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ABSTRACT 
In 2008 the global prevalence of hypertension [high blood pressure (BP), systolic ≥140 
mmHg and/or diastolic ≥90 mmHg] was around 40% in adults > 25 yrs of age, according to the 
2013 WHO statistics. Hypertension is a major risk factor for myocardial infarction, heart failure 
and stroke. Currently, around 20% of the Canadian population is affected by hypertension. 
Hypertension is more closely associated with diabetes. More than two thirds of people with 
diabetes have hypertension, alongwith increased activity of the renin angiotensin aldosterone 
(RAAS) system. The RAAS plays a major role in maintaining fluid balance, vascular tone and 
BP. The components of the RAAS include the hormone renin, which cleaves angiotensinogen, a 
circulating inactive peptide into angiotensin I. Angiotensin converting enzyme (ACE) converts 
angiotensin I into the active peptide angiotensin II (Ang II). Ang II causes vasoconstriction, 
sodium reabsorption from the kidney tubules and also release of the hormone, aldosterone, from 
the adrenal cortex. The epidemic of hypertension, diabetes and obesity is widely attributed to a 
high carbohydrate diet, containing mainly high fructose corn syrup and sucrose. However, the 
underlying molecular mechanisms are far from clear. A high fructose diet increases BP in 
Sprague-Dawley (SD) rats; along with elevated plasma and aortic levels of methylglyoxal (MG). 
MG is a reactive dicarbonyl compound mainly formed as an intermediate during glycolysis. 
Small amounts of MG are also formed during amino acid (threonine) and fatty acid metabolism. 
MG reacts with certain proteins to form irreversible advanced glycation end products (AGEs). 
MG has high affinity for arginine, lysine and cysteine.  Plasma MG levels are increased in 
hypertensive rats and diabetic patients. However, it is not yet clear whether MG is the cause or 
effect of hypertension. Moreover, safe and specific MG scavengers are not available.  
The aim of the project was to determine the effect of MG and a high fructose diet on the 
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RAAS and the BP in male SD rats.  The hypothesis that L-arginine, and its inactive isomer D-
arginine, can efficiently scavenge MG in vitro, was also tested.  
Male SD rats were treated with a continuous infusion of MG with a subcutaneous minipump 
for 4 weeks, or with a high fructose diet (60% of total calories) for 16 weeks. We also used 
isolated aortic rings from 12 week old normal male SD rats to study endothelial function. Organs 
/ tissues, cultured human umbilical vein endothelial cells (HUVECs) and vascular smooth 
muscle cells (VSMCs) were used for molecular studies. HPLC, Western blotting and Q-PCR 
were used to measure MG, reduced glutathione (GSH), proteins and mRNA, respectively. siRNA 
for angiotensinogen and the receptor for advanced glycation endproducts (RAGE) were used to 
study mechanisms. 
MG treated rats developed a significant increase in BP and plasma levels of aldosterone, 
renin, angiotensin and catecholamines. MG level, and protein and mRNA for angiotensin, AT1 
receptor, adrenergic α1D receptor and renin were significantly increased in the aorta and/or 
kidney of MG treated rats, a novel finding. Alagebrium, a MG scavenger and AGEs breaker, 
attenuated the above effects of MG. Treatment of cultured VSMCs with MG or high glucose 
(25mM) significantly increased cellular MG, and protein and mRNA for nuclear factor kappa B 
(NF-κB), angiotensin, AT1 and α1D receptors, which were prevented by inhibition of NF-κB, and 
by alagebrium. Silencing of mRNA for RAGE prevented the increase in NF-kB induced by MG. 
Silencing of mRNA for angiotensinogen prevented the increase in NF-κB, angiotensin, AT1 and 
α1D receptors’ protein. Fructose treated rats developed a significant increase in BP.  MG level and 
protein and mRNA for angiotensin II, AT1 receptor, adrenergic α1D receptor and renin were 
significantly increased, whereas GSH levels were decreased, in the aorta and/or kidney of 
fructose fed rats.  The protein expression of the receptor for AGEs (RAGE) and NF-κB were also 
iv 
 
significantly increased in the aorta of fructose fed rats.  MG treated VSMCs showed increased 
protein for angiotensin II, AT1 receptor, and α1D receptor. The effects of fructose and MG were 
attenuated by metformin, a MG scavenger and AGEs inhibitor. In experiments to test the MG 
scavenging action of arginine, both D-arginine and L-arginine prevented the attenuation of 
acetylcholine-induced endothelium-dependent vasorelaxation by MG and high glucose. 
However, the inhibitory effect of the NOS inhibitor, Nω-nitro-L-arginine methyl ester, on 
vasorelaxation was prevented only by L-arginine, but not by D-arginine. MG and high glucose 
increased protein expression of arginase, a novel finding, and also of NADPH oxidase 4 and NF-
κB, and production of reactive oxygen species in HUVECs and VSMCs, which were attenuated 
by D- and L-arginine. However, D- and L-arginine did not attenuate MG and high glucose-
induced increased arginase activity in VSMCs and the aorta. D- and L-arginine also attenuated 
the increased formation of the MG-specific AGE, Nε-carboxyethyl lysine, caused by MG and 
high glucose in VSMCs.  
In conclusion, MG activates NF-κB through RAGE and thereby increases renin angiotensin 
levels, a novel finding, and a probable mechanism of increase in BP. There is a strong association 
between elevated levels of MG, RAGE, NF-κB, mediators of the RAAS and BP in high fructose 
diet fed rats. Arginine attenuates the increased arginase expression, oxidative stress, endothelial 
dysfunction and AGEs formation induced by MG and high glucose, by an endothelial NOS 
independent mechanism.  
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CHAPTER 1 
 
INTRODUCTION AND LITERATURE REVIEW 
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1.1 Hypertension 
1.1.a Definition 
Hypertension, also defined as high blood pressure, is a medical condition in which the 
blood pressure (BP) in the arteries stays persistently elevated. BP is the force of blood pushing 
up against the arterial vessel walls. The higher the pressure, the harder it requires the heart to 
pump the blood. BP is measured as systolic pressure i.e., peak pressure in the arteries, and 
diastolic pressure i.e., minimum pressure in the arteries. Normal BP is usually below 120/80 
mmHg where 120 mmHg represents systolic and 80 mmHg represents diastolic pressure (Giles 
et al., 2009; Chobanian et al., 2003). A BP value between 120/80 mmHg and 139/89 mmHg is 
called prehypertension and BP above 140/90 mmHg is considered hypertension (Table 1-1). 90-
95% cases of hypertension are characterized as primary (formerly also known as essential 
hypertension) with no apparent medical cause. 5-10% cases are secondary hypertension with a 
known cause such as kidney disease, tumors and heart disease (Carretero & Oparil, 2000). 
Although the exact cause/causes of hypertension is/are not known, there are several factors such 
as smoking, obesity, diabetes, lack of physical activity,  high levels of salt intake, stress, aging, 
and tumors, which contribute to its development (Klaus et al., 2009; Elley et al., 2002) (Table 1-
2). Hypertension is a major risk factor for stroke, ischemic heart disease, heart failure and 
chronic kidney disease (Coca et al., 2008; Hatmi et al., 2007). 
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Stages of Hypertension 
BP 
Category SBP (mmHg) DBP (mmHg) 
Normal <120 <80 
Prehypertension 120-139 80-89 
Hypertension, Stage 1 140-159 90-99 
Hypertension, Stage 2 ≥160 ≥100 
 
Table 1-1: Stages of hypertension based on change in systolic and diastolic blood 
pressure. SBP – systolic blood pressure, DBP – diastolic blood pressure. Adapted from JNC 
7, 2004. http://www.nhlbi.nih.gov/guidelines/hypertension/phycard.pdf 
 
1.1.b Prevalence  
In 2013, the World Health Organization chose hypertension as the theme for the World 
Health Day which was celebrated on April 7, 2013 (Campbell et al., 2013) 
(http://www.cdc.gov/features/worldhealthhypertension/). The World Health Day highlights a 
topic that is a public health concern. The global prevalence of high BP in adults aged 25 years 
and above was around 40% (around 2.7 billion out of 6.7 billion people) in 2008. The number of 
people with uncontrolled hypertension was around 600 million in 1980 and rose to 1 billion by 
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the year 2008. High BP is estimated to cause 7.5 million deaths worldwide every year, which 
accounts for about 12.8% of the total number of deaths 
(http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/). Canada has the 
highest reported national rates of awareness, treatment, and control of high BP in the world. The 
prevalence of hypertension in Canada has remained fairly constant at around 20% of the 26 
million people included in the retrospective study, for the past three decades (1985-2011) 
(Campbell et al., 2013). 
 
 
Lifestyle 
 
Risk of hypertension 
High dietary sodium 32% 
Obesity 32% 
Low dietary potassium   17% 
Less physical activity  17% 
High alcohol intake 3% 
  
Table 1-2: Lifestyle causes of increase in the BP. Adapted from Can J Cardiol. 2013; 
29:415-417. 
 
1.1.c Classification of Hypertension 
Hypertension can also be classified (Table 1-3) based on cardiovascular risk factors, early 
disease markers and target organ disease as follows: 
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Classification 
 
Normal 
 
Hypertensi
on 
Stage I 
 
Hypertension 
Stage 2 
 
Hypertension 
Stage 3 
 
Description 
 
Normal 
BP & no 
CVD 
 
Intermittent 
or occasional 
BP elevation 
and early 
CVD 
 
Sustained 
elevation of BP or 
progressive CVD 
 
Marked 
elevation of BP 
or advanced 
CVD 
 
Cardiovascular risk 
factors 
 
- 
 
Several risk 
factors present 
 
Many risk 
factors 
 
Many risk 
factors 
 
Early disease markers 
 
- 
 
Present 
 
Present 
 
Present with 
progression 
 
Target organ disease 
 
- 
 
- 
 
Early signs 
 
Present 
 
Table 1-3: Classification of hypertension. Adapted from J Clin Hypertens. 2009 
Nov;11(11):611-4. 
Cardiovascular risk factors - Aging, obesity, dyslipidemia, insulin resistance, kidney disease etc. 
6 
 
Early disease markers - Loss of nocturnal BP dipping, left ventricular hypertrophy, artery 
stiffness, endothelial dysfunction, microalbuminuria, elevated serum creatinine. 
Target organ disease - Left ventricular hypertrophy, peripheral arterial disease, stroke, heart 
failure and neuropathy 
CVD – cardiovascular disease 
 
1.1.d Regulation of BP 
There are many factors which can influence BP like diet, exercise, disease condition and 
stress. One main physical factor involved in BP physiology is the volume of blood. When there 
is more blood present in the body, the rate of blood return to the heart is higher resulting in 
higher cardiac output (Freis, 1975). Another factor influencing BP is vascular resistance or better 
still, peripheral vascular resistance. Higher the resistance, higher will be the pressure upstream 
from the resistance to blood flow. Resistance is calculated by vessel radius, vessel length, and 
blood viscosity. Larger the vessel radius, lower the resistance, and longer the vessel, higher is the 
resistance. Smoothness of the vessel wall is affected by the buildup of fatty deposits on the 
arterial walls and thickness or viscosity of the fluid (Rosenson et al., 2004). If the blood gets 
thicker, this results in an increase in arterial pressure. Certain medical conditions like anemia 
(low red blood cell count) reduce viscosity of the blood. 
The short term regulation of BP is controlled by the sympathetic nervous system (SNS) 
and the renin angiotensin aldosterone (RAAS) system while  long term BP is controlled by the 
kidney.  
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Normal BP is usually below 120/80 mmHg. Parameters influencing systolic pressure 
include stroke volume, systolic rate and arterial compliance. An increase in stroke volume, 
systolic rate and a decrease in compliance cause an increase in systolic pressure. Factors 
influencing diastolic pressure include vascular resistance, heart rate and systolic pressure. 
Diastolic pressure is directly proportional to these factors (Prasad, 2009). 
Baroreceptor and chemoreceptor reflex 
Baroreceptors, located in the carotid sinus at the bifurcation of the common carotid artery 
and aortic arch, respond to acute elevations in BP by causing a reflex vagal bradycardia. Cardio 
pulmonary receptors, located in the pulmonary vessels and in the walls of the right atrium and 
the ventricles of the heart, likewise respond to increases in atrial filling by causing  bradycardia  
through inhibition of cardiac SNS, increasing atrial natriuretic peptide (ANP) release and 
inhibition of vasopressin release (Prasad, 2009). 
Chemoreceptors, located at the bifurcation of the carotid artery and aortic arch, respond 
to changes in blood pO2, pCO2 and pH. Chemoreceptors are stimulated when either pO2, pH, or 
the blood flow in the arteries is very low, or when the pCO2 is high. In response to these changes, 
the chemoreceptors send impulses to cause vasoconstriction and increase the vascular resistance, 
heart rate and stroke volume via increased sympathetic activity (Prasad, 2009). 
Sympathetic nervous system 
The sympathetic nervous system (SNS) through renal sympathetic nerves also plays an 
important role in BP regulation by stimulating renin release from the juxtaglomerular apparatus 
(Joyner et al., 2010). α1-adrenergic receptors, one of the subtypes of adrenergic receptors, belong 
to the G protein-coupled receptor (GPCR) family and mediate responses to norepinephrine and 
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epinephrine. α1-adrenergic receptors are further subdivided into α1A, α1B and α1D using receptor 
binding and molecular cloning studies (Zhong & Minneman, 1999). All three α1-adrenergic 
receptor subtypes act via Gq/11 signaling pathway.  Gq/11 signaling activation in turn leads to 
activation of phospholipase C, generation of inositol trisphosphate and diacylglycerol, and 
finally an increase in intracellular calcium levels (Piascik & Perez, 2001; Pupo & Minneman, 
2001). Although all three α1 adrenergic receptor subtypes activate the same Gq/11 protein 
signaling pathway, due to their different tissue distributions, they play distinct functional roles. 
α1A adrenergic receptor is highly expressed in the prostate and is the dominant receptor 
controlling benign prostatic hypertrophy, and is thus an important therapeutic target for the 
treatment of benign prostatic hyperplasia (Nagarathnam et al., 1998). α1D is the major adrenergic 
receptor in the aorta and is responsible for the contraction of the aorta (Fan et al., 2009). WB 
4101[13], (+)-niguldipine (Boer et al., 1989), and 5-methylurapidil (Gross et al., 1988) have 
been used as α1A selective antagonists, and BMY7378 (Goetz et al., 1995) is used to characterize 
α1D adrenergic receptors. However, little progress has been made to identify α1B adrenergic 
receptor selective compounds. Three α2 receptor subtypes have been identified, α2A/D, α2B and 
α2C. Most of the classical effects of α2 adrenergic stimulation are mediated by pre-synaptic α2A 
receptors, which inhibit the release of norepinephrine, and cause a decrease in BP. α2B adrenergic 
receptors are mostly found at postsynaptic sites where they produce vasoconstriction and thus 
have effects opposite to those of α2A receptors. α2C adrenergic receptors may mediate a 
hypothermic response and do not have cardiovascular effects (Joyner et al., 2010). 
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Renin angiotensin aldosterone system 
The activity of the RAAS plays an important role in BP regulation. Renin is a 340 amino 
acid protein with a molecular weight of 37 kDa.  As shown in (Fig 1-1), renin is secreted by the 
kidney from granular cells of the juxtaglomerular apparatus in response to a decrease in the BP, 
low salt levels in the nephron and an increase in the SNS activity. Renin breaks down 
angiotensinogen, produced by the liver, to an inactive decapeptide, angiotensin I. Angiotensin I 
is further converted into the active octapeptide angiotensin II (Ang II) by the angiotensin 
converting enzyme (ACE) within the capillaries (Atlas, 2007). 
  The amount of renin in the plasma acts as a limiting factor for Ang II production. Apart 
from Ang II generated in the circulation, blood vessels capture circulating renin and 
angiotensinogen and produce Ang II at the surface of their wall. Many tissues like blood vessels, 
heart, kidney, and brain possess all components of the renin angiotensin system and generate 
Ang II inside their cells. Ang II is involved in electrolyte balance, blood volume and pressure 
homeostasis. The most important action of Ang II is vasoconstriction produced directly as well 
as by increasing epinephrine/norephinephrine release and increasing central sympathetic outflow. 
Vasoconstriction involves arterioles and venules and occurs in all vascular beds. Ang II induced 
vasoconstriction promotes movement of fluid from the vascular to the extravascular 
compartment. Ang II increases the force of myocardial contraction by increasing Ca
2+
 influx.  
Aldosterone is a steroid hormone belonging to the mineralocorticoid family. It is 
produced by the zona glomerulosa of the adrenal cortex in the adrenal gland. Aldosterone plays a 
central role in BP regulation by acting on the distal tubules and collecting ducts of the nephron, 
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increasing reabsorption of sodium ions and water in the kidney, to cause the conservation of 
sodium, secretion of potassium and increased water retention (Booth et al., 2002). 
ADH, also known as antidiuretic hormone, is synthesized in the hypothalamus and stored 
in the posterior pituitary. ADH release is increased by Ang II. ADH plays a role in water 
reabsorption in the renal tubules, which in turn causes increased fluid volume, cardiac output and 
later on increased vascular resistance and then finally increased arterial pressure (Prasad, 2009). 
 
Renin
Angiotensin II
ACE
Sympathetic activity
Aldosterone secretion
Vasoconstriction, increase in B.P
ADH secretion
 
 
Figure 1-1. Pathway of regulation of BP by the renin angiotensin aldosterone system. 
Adapted from Nature Rev Drug Disc. 2002;1:621-636. http://www.acibademinternational.com/  
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Although the pharmacological inhibition of the RAAS using ACE inhibitors and AT1 
receptor blockers can be beneficial in certain conditions including hypertension, a growing body 
of evidence suggests that blocking the RAAS at its initial step, i.e., renin inhibition may provide 
an effective RAAS suppression. Aliskiren is an orally active direct renin inhibitor and was 
approved by the U.S. Food and Drug Administration in 2007 for the treatment of primary 
hypertension. Aliskiren, by inhibiting renin, prevents  angiotensin I  generation  from  
angiotensinogen,  and  thus subsequently  prevents   the  activation  of the  rest  of  the RAAS  
(Wood et al., 2003).   
Angiotensin I can also be converted to angiotensin (1-9) by angiotensin converting 
enzyme 2 (ACE2) and angiotensin (1-9) can be converted to angiotensin (1-7) by ACE. 
Angiotensin (1-7) is an active member of the RAAS system and has functions opposite to those 
of Ang II. Angiotensin (1-7) acts via a G protein-coupled receptor called Mas (Santos et al., 
2003; Santos et al., 2005). AVE0991  is  a  non-peptide  angiotensin (1–7)  receptor  Mas 
agonist,  and  its  administration  in  coronary artery  ligated  rats  attenuated  post-ischemic  
heart failure  induced  by  myocardial  infarction (Ferreira et al., 2007a). AVE0991 also 
prevented isoproterenol-induced impairment in heart function/remodeling in the rat (Ferreira et 
al., 2007b). It has been reported recently that angiotensin (1-9) antagonizes pro-hypertrophic 
signaling in cardiomyocytes via angiotensin type 2 (AT2) receptors (Flores-Muñoz et al., 2011). 
Renin, ACE2, angiotensin (1-7) and angiotensin (1-9) are potential therapeutic targets and need 
further investigation for the prevention and treatment of cardiovascular disorders (Balakumar et 
al., 2011).  
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1.1.e Pathogenesis of Hypertension 
In general, hypertension is caused by both genetic and environmental factors (Oparil et 
al., 2003). The hereditability of blood pressure in humans has been estimated at 30-50% (Ehret 
& Caulfield., 2013). 
Although several factors contribute to the pathogenesis of hypertension, renal 
mechanisms play a fundamental role.  Mean arterial pressure is the product of cardiac output and 
systemic vascular resistance and patients with hypertension may either have an increase in 
cardiac output, an increase in systemic vascular resistance, or both.  Regulation of normal BP is 
dependent on the balance between cardiac output and peripheral vascular resistance and most 
patients with primary hypertension have a normal cardiac output but raised peripheral resistance 
(Beevers et al., 2001).  In young patients the cardiac output is often elevated, while in older 
patients increased systemic vascular resistance and increased vascular stiffness are the 
contributing factors. The tone of the vessel may be elevated due to increased release of peptides 
(angiotensin, endothelin) or increased alpha receptor stimulation. The final outcome is an 
increase in cytosolic calcium in vascular smooth muscle cells (VSMCs) causing vasoconstriction 
(Foex & Sears, 2004). Hypertension (Fig 1-2) is usually a result of complex interaction of 
genetic, environmental and demographic factors. Hypertension also causes vascular and cardiac 
remodeling and hypertrophy which in turn leads to a change in the structure and function of the 
heart and vessel wall (Mayet & Hughes, 2003). Enhanced peripheral sensitivity to 
norephinephrine and decreased sensitivity to baroreceptor reflexes has also been observed in 
hypertensive patients (Foex & Sears, 2004). Increased activity of the RAAS has also been 
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suggested as one of the contributing factors in the pathogenesis of hypertension (Oparil et al., 
2003). 
 
Figure 1-2. Pathogenesis of hypertension. Adapted from Ann Intern Med.2003;139:761-776. 
Abbreviations: Ald - aldosterone; Ang - angiotensinogen; CO – cardiac output; GIT – 
gastrointestinal tract; Ins - insulin; SA – sympathetic activation. 
  
SNS over activity increases BP via stimulation of the heart, peripheral vasculature, and 
kidney thus causing increased cardiac output, increased vascular resistance, and fluid retention 
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(Mark, 1996). Chronic stimulation of the SNS induces vascular remodeling and left ventricular 
hypertrophy, by direct action of norepinephrine on its own receptors and indirectly via release of 
various trophic factors such as transforming growth factor, insulin-like growth factor 1, and 
fibroblast growth factors (Brook & Julius, 2000). Sympathetic stimulation is also increased in the 
kidney in hypertensive patients compared with normotensive control patients.  Psychological 
stress is also one of the contributing factors to increases in BP. It has been reported that exposure 
to stress increases sympathetic outflow, and constant stress induces vasoconstriction which in 
turn may lead to vascular hypertrophy, increases in peripheral resistance and BP (Light, 2000). 
Hyperuricemia, characterized by abnormally high uric acid levels in the blood, is also associated 
with hypertension in humans, but whether it is an independent risk factor or only a marker for 
associated CVD risk factors is not clear (Rich, 2000; Culleton et al., 1999). In human patients 
hyperuricemia is associated with renal vasoconstriction (Messerli et al., 1980) and is positively 
correlated with plasma renin activity in hypertensive patients (Saito et al., 1978), thus indicating 
that uric acid could have adverse effects that are mediated by an activated RAAS system. 
 
1.1.f  Hypertension in Diabetes 
Approximately 70% of patients with diabetes have hypertension and it is twice more 
common in patients with diabetes than without it (Arya, 2003). Hypertension in diabetic patients 
causes a significant risk of other complications like retinopathy, neuropathy, nephropathy and 
ischemic vascular disease (Arya, 2003). Diabetes mellitus is also an independent risk factor for 
coronary artery disease and the risk is significantly higher when hypertension is present. In 
patients with type 1 diabetes, diabetic nephropathy is the commonest cause of hypertension in 
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patients. In patients with type 2 diabetes hypertension commonly occurs without abnormal renal 
function and is often associated with obesity. Diabetes and insulin resistance can aggravate 
hypertension by stimulating the renin angiotensin system, the SNS and sodium retention (Lago et 
al., 2007; Campbell et al., 2011). Increased VSMC proliferation has also been observed under 
diabetic conditions. High BP and elevated blood glucose levels can impair vascular endothelial 
cell function which in turn leads to increased oxidative stress (Kolluru et al., 2012; Giacco & 
Brownlee, 2010). Patients with diabetes also have increased vascular reactivity (Chittari et al., 
2011).  
The pathogenesis of hypertension in diabetes is multifactorial and complex. Interactions 
between genetic, environmental and biological factors such as sedentary behavior, unhealthy 
diet, sodium retention, obesity, autonomic derangements, arterial stiffening, and endothelial 
dysfunction seem to play an important role (Campbell, 2011). Insulin resistance plays a pivotal 
role in the pathogenesis of hypertension. In many randomized controlled trials patients with 
diabetes have benefited from a more aggressive treatment of hypertension. Insulin resistance 
plays a role in the development of hypertension via defects in the insulin signaling pathway and 
associated cardiovascular and metabolic disorders. Insulin resistance and its accompanying 
hyperglycemia can lead to increased sympathetic activity, increased RAAS activity, suppressed 
atrial natriuretic peptide activity, and increased sodium retention with volume expansion, cardiac 
hyperactivity, and dyslipidemia. Chronic hyperglycemia causes increased oxidative stress 
(Sampanis & Zamboulis, 2008). Pregnant women with hypertension and diabetes are at 
increased risk of developing pre-ecclampsia (Allison et al., 2013), and children with diabetes and 
hypertension are vulnerable to end organ disease (Lago et al., 2007). 
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1.1.g Glucose and Fructose Induced Hypertension 
The intake of refined sugar in the diet increased dramatically in the latter part of the 
twentieth century after it was widely manufactured from sugar cane (Yudkin, 1967). In the 1970s 
the introduction of high-fructose corn syrup, a mixture of glucose and fructose in varying 
proportions, further increased the carbohydrate load in the diet because high fructose corn syrup 
is widely used in soft drinks, fruit punches, bread, and processed foods (Yudkin, 1967). In 1960s 
Yudkin proposed that the sugar in the diet, and not fat, is the primary cause of increased 
incidence of diabetes and various cardiovascular diseases (Yudkin, 1964). Epidemiologic studies 
show an association of soft drink consumption with obesity, hypertension, and diabetes (Schulze 
et al., 2004; Bray et al., 2004). 
Two thirds of the patients with primary hypertension have an abnormal blood glucose 
metabolism (Garcia-Puig et al., 2006). Several studies have shown that administration of a high 
carbohydrate diet significantly increases BP in animals and humans. In a clinical study, the 
administration of sucrose significantly increased body weight, serum triacylglycerols, and 
systolic BP (Raben et al., 2002). Similarly, healthy adults fed a diet of 33% sucrose for 6 weeks 
showed an increase in BP (Israel et al., 1983). Oral administration of 10% D-glucose to normal 
rats for 3 weeks induced hypertension (Tom et al., 2011). Male Sprague-Dawley (SD) rats fed a 
glucose-rich diet developed a 7% increase in BP compared to rats fed a normal diet. Higher 
norepinephrine excretion in glucose fed rats suggests that increased SNS activity might 
participate in the glucose-induced rise in BP (Kaufman et al., 1991). Fructose-fed SD rats have 
been widely used as a model of insulin resistance (Hwang et al., 1987; Jia & Wu, 2007) and 
these rats also develop hypertension. For example, SD rats fed with a diet containing 66% 
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fructose as a percentage of total calories for approximately 2 weeks developed a significant 
increase in systolic blood pressure from 124 ± 2 to 145 ± 2 (SEM) mmHg, whereas no change 
occurred in the control group. In addition, hyperinsulinemia and hypertriglyceridemia were 
associated with hypertension in fructose-fed rats (Hwang et al., 1987). In other studies male SD 
rats fed a 60% fructose diet for 8-11 weeks developed a significant increase in systolic BP, other 
features of the metabolic syndrome (Nakagawa et al., 2006) and pathologic changes in the 
kidney (Sanchez-Lozada et al., 2007; Gersch et al., 2007). We have shown that fructose-fed SD 
rats have elevated levels of MG (Wang et al., 2008), a product of fructose metabolism. Even 
lower doses of fructose (10% in drinking water) given to SD rats for 8 weeks induced a 
significant increase in systolic BP and microvascular changes in the kidney (Sanchez-Lozada et 
al., 2007). High dietary carbohydrate-induced hypertension is associated with an increase in uric 
acid concentrations (Sanchez-Lozada et al., 2007; Gersch et al., 2007) with a consequent 
increase in oxidative stress (Sautin et al., 2007) and inhibition of NO production (Khosla et al., 
2005). One study has reported that fructose-induced hypertension is mediated by an increase in 
salt re-absorption by the intestine and kidneys, and these effects are mediated by transporters 
Slc26a6 and Slc2a5 (Singh et al., 2008).  
 
1.1.h Treatment of Hypertension 
Treatment for hypertension can be achieved with lifestyle changes along with 
medications. There are different classes of drugs available for the prevention and management of 
hypertension.  
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ACE inhibitors are often the first choice drugs in all grades of primary hypertension as 
well as renovascular hypertension. They include captopril, enalapril, lisinopril etc. (Ajayi et al., 
1985). ACE inhibitors increase plasma kinin levels such as bradykinin and potentiate the 
hypotensive action of bradykinin. ACE inhibitors induce hypotension by decreasing total 
peripheral resistance. The arterioles dilate and compliance of large arteries is increased. Both 
systolic and diastolic BP fall without change in cardiac output. They are the most appropriate 
drugs for diabetic nephropathy, left ventricular hypertrophy, congestive heart failure and angina 
pectoris (Brown & Vaughan, 1998). 
Over the years several nonpeptide orally active AT1 receptor antagonists have been 
developed. Losartan, candesartan and telmisartan are included in this class. AT1 receptor 
antagonists are now first line antihypertensive drugs alternative to ACE inhibitors in efficacy, 
with the advantage of not inducing cough, and with a low incidence of angioedema. AT1 receptor 
antagonists cause competitive antagonism of Ang II and are 10,000 times more selective for AT1 
than AT2 receptors. They block all the actions of Ang II including vasoconstriction, central and 
peripheral sympathetic stimulation, release of aldosterone and vasopressin release (Fabia et al., 
2007; Unger, 2001).  
A large number of chemically diverse calcium channel blockers (CCBs) with different 
pharmacological profiles have been produced. Three important classes are: verapamil - a 
phenylalkylamine hydrophilic papaverine congener, nifedipine - a dihydropyridine (lipophilic), 
diltiazem - a hydrophilic benzothiazepine. The dihydropyridines are the most potent CCBs.  
CCBs cause smooth muscle (vascular) relaxation by decreasing intracellular availability of Ca
2+
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by blocking L-type Ca
2+ 
channels. They lower BP by decreasing peripheral resistance without 
compromising cardiac output (Sica, 2007; Schoen & Tanzi, 2008). 
Diuretics have been the standard antihypertensive drugs over the last 4 decades. These 
include thiazide diuretics like chlorthalidone, which act by decreasing extracellular fluid volume 
and ultimately leading to a decrease in total peripheral resistance and fall in BP. Another class of 
drugs in this category is the high ceiling diuretics like furosemide which act by decreasing 
plasma volume and cardiac output (Ernst & Moser, 2009; Musini et al., 2009).  
Beta adrenergic receptor blockers are mild antihypertensives and do not lower the BP in 
normotensives. Alpha adrenergic receptor blockers or antagonists like prazosin dilate both 
resistance and capacitance vessels, with the former effect predominating. They cause a reduction 
in total peripheral resistance and mean BP with a slight decrease in venous return and cardiac 
output (Cruickshank, 2010; Stokes & Marwood, 1985). 
Another group of antihypertensive drugs is central sympatholytics like clonidine, which 
is a partial agonist and has a high affinity for α2A receptors in the brainstem. The major effect of 
α2A receptor stimulation is a decrease in the sympathetic outflow resulting in a fall in BP and 
bradycardia, which is also due to enhanced vagal tone (Vongpatanasin et al., 2011). 
 
1.2 Methylglyoxal  
1.2.a Source and Chemistry of Methylglyoxal 
Methylglyoxal (MG) (Fig 1-3), also called 2-oxopropanal or pyruvaldehyde, is an 
aldehyde with two carbonyl groups, and hence is also called a dicarbonyl compound. It is a 
yellow liquid with a pungent odour and has a molecular weight of 72.06. MG is both an aldehyde 
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and a ketone. Since MG has two α,β carbonyl groups, this makes it a highly reactive compound, 
reacting with exposed arginine, lysine and cysteine residues of proteins, and with other 
macromolecules such as DNA, in the body.  
 
 
Figure 1-3. Chemical structure of methylglyoxal 
 
1.2.b Synthesis and Degradation of MG 
MG was first synthesized from iso-nitrosoacetone in the presence of dilute sulfuric acid 
along with the formation of glycol, formaldehyde and formate by Von Penchmann (Von 
Penchmann, 1887), who first developed the method for the synthesis of MG. MG can also be 
formed from acid hydrolysis of methylglyoxal dimethylacetal and from the oxidation of acetone 
with selenium dioxide followed by distillation under nitrogen atmosphere (Kalapos, 1999).  
In living organisms (Fig 1-4), MG is an endogenous metabolite and has been proposed to 
be primarily formed during glycolysis from the triose phosphate intermediates. Other important 
precursors of MG, believed to produce lower amounts of MG, include aminoacetone, produced 
from amino acids L-threonine and glycine during protein catabolism, and ketone bodies such as 
acetone from fatty acid oxidation. MG formation from these sources involves various enzymatic 
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and nonenzymatic reactions, but the main enzymes which catalyze MG formation from these 
precursors include: MG synthase, semicarbazide-sensitive amine oxidase (SSAO) and mono-
oxygenase (MO). MG synthase catalyzes the conversion of triose phosphate intermediate, 
dihydroxyacetone phosphate (DHAP), into MG, under inadequate availability of inorganic 
phosphate. SSAO catalyzes the deamination of aminoactone to produce aldehyde, ammonia and 
hydrogen peroxide. Two enzymes, i.e. acetone and acetol mono-oxygenase (AMO), catalyze the 
conversion of acetone to acetol and acetol to MG, respectively, during fatty acid oxidation. 
SSAO is primarily found in the cytoplasm of adipose tissue, VSMCs, plasma and endothelial 
cells (Thornalley, 1996; Desai & Wu, 2007). 
MG formed is rapidly detoxified to D-lactic acid by the glyoxalase system, which 
consists of 2 enzymes, glyoxalase I and II, and uses reduced glutathione (GSH) as a cofactor. 
GSH binds to MG and presents it to glyoxalase I, which first converts MG irreversibly to (S)-D-
lactoylglutathione and then by glyoxalase II to D-lactate. Hence, adequate availability of cellular 
GSH is crucial for normal catabolism of MG in the body. Also, GSH-related enzymes, including 
glutathione peroxidase and glutathione reductase are equally important as they are involved in 
the synthesis and recycling of GSH (Thornalley, 1990). 
22 
 
Desai & Wu. Recent Pat Cardiovasc Drug Discov; 2007, 2, 89.
Glyoxalse I
Lactoylglutathione
Glyoxalase II
GSH
D-Lactate
Fatty acids
Acetone, Acetol
AMO
Protein
Aminoacetone
Glycine, Threonine
SSAO
SorbitolGlucose
DHAP
G 3 P
Pathway of MG formation
Methylglyoxal
 
 
Figure 1-4. Metabolic pathways of MG formation and degradation. Adapted from 
Metabolism. 2008; 57(9):1211-20. 
Schematic showing pathways, substrates and enzymes involved in the formation of MG in the 
body.  
Abbreviations: AMO – acetol/acetone monooxygenase; DHAP – dihydroacetone phosphate; F-
1,6-di-P – fructose-1,6-diphosphate; G-3-P – glyceraldehyde-3-phosphate; GSH – reduced 
glutathione; SSAO – semicarbazide-sensitive amine oxidase; ROS – reactive oxygen species.  
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1.2.c Plasma and Tissue Levels of MG 
Under normal conditions, the plasma levels of MG are between 0.5 and 1.5 µM (Jia & 
Wu, 2007; Wang et al., 2007) and the levels increase as much as 2 to 4 fold under hypertensive 
and diabetic conditions (Wang et al., 2007; Beisswenger et al., 1999). An increased body of 
evidence suggests that there is a link between increased MG formation and hypertension but the 
exact mechanism is far from clear. Previous studies have reported higher MG levels in the 
plasma of spontaneously hypertensive  rats (SHR) of 13.8 µM at 8 weeks of age and 33 µM at 20 
weeks as compared to Wistar Kyoto (WKY) rats at the same age (9.1 and 14.2 µM). In the aorta 
and kidney of SHR, the MG levels were 2.5 nmol/mg protein and 0.3 nmol/mg protein, 
respectively, as compared to the WKY rats (1.5 nmol/mg protein and 0.2 nmol/mg protein, 
respectively) at the same age (Wang et al., 2004; Wang et al., 2005). In Sprague-Dawley rats fed 
with a high fructose diet for 9 weeks, there was a significant increase in serum MG levels to 3.2 
µM compared to 1.8 µM in the control rats and the effect was attenuated by the MG scavenger 
N-acetyl cysteine (NAC) (Jia and Wu, 2007). Rat VSMCs incubated with a high concentration of 
glucose or fructose lead to increased MG formation along with an increase in oxidative stress 
(Dhar et al., 2008). High MG levels are related to diabetic microvascular complications 
including retinopathy, nephropathy and neuropathy, and diabetic macrovascular complications 
such as atherosclerosis.  
 
1.2.d MG and Advanced Glycation Endproducts 
Advanced glycation endproducts (AGEs) are harmful chemical entities and are complex, 
heterogeneous compounds produced from chemical modification of physiologic molecules of the 
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body during metabolic processes and have been implicated in diabetes related complications 
(Desai & Wu, 2007).   
AGEs as shown in (Fig 1-5) are formed when reducing sugars such as glucose, react non-
enzymatically with the amino group of proteins at their N terminal, and with lipids and nucleic 
acids. The non-enzymatic reaction is known as glycation and is an outcome of excess glucose in 
the body. It starts with the carbonyl group of sugar reacting with the protein to form a Schiff 
base, an unstable intermediate (Oya et al., 1999; Desai & Wu, 2007). The Schiff base later 
undergoes an arrangement to form a stable Amadori product and this stable Amadori product can 
undergo oxidation, degradation or rearrangement to form AGEs. This process is also known as 
the Maillard reaction or “browning reaction”, when amino acids form a brown coloured product 
while heated in the presence of reducing sugars (Maillard, 1916).  
If Amadori products undergo oxidation then the end products formed are known as 
glycoxidation products such as AGEs like pentosidine and carboxymethyl-lysine (CML) (Ahmed 
et al., 1986; Sell & Monnier, 1989).  Amadori rearrangement and sugar molecule fragmentation 
leads to the formation of reactive intermediate products known as α-dicarbonyls or oxoaldehydes 
and include 3-deoxyglucose (3-DG), MG and glyoxal. The accumulation of the dicarbonyls leads 
to carbonyl stress causing demage and oxidative stress in the body (Chellan & Nagaraj, 1999). 
These AGEs affect the normal function of various proteins and enzymes by forming 
covalent cross-links between proteins (Reddy et al., 1995) and thus lead to severe damage 
including diabetic retinopathy, nephropathy and aging.  
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Figure 1-5. Pathway of AGEs formation by MG. 
MG can also lead to AGEs formation. MG and two other oxoaldehydes (3-DG and 
glyoxal) are considered to be the major source of intracellular AGEs formation. The non-
enzymatic reaction of MG, not degraded by the glyoxalase system, with arginine or lysine 
residues of proteins forms irreversible AGEs, leading to cross linking and denaturation of 
proteins. The irreversible reaction of MG with arginine forms the AGEs, hydroimidazolone, Nε-
(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine and argpyrimidine, whereas the reaction 
between MG and lysine forms the AGEs Nε-carboxyethyllysine (CEL) and Nε-
carboxymethyllysine (CML). Carbonyl precursors (MG, 3-DG and glyoxal) also form non-
oxidative AGEs, which are non-fluorescent, such as methylglyoxal-lysine dimer (MOLD), 
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glyoxal-lysine dimer (GOLD) and deoxyglucosone-lysine dimer (DOLD). These AGEs can be 
detected by HPLC, ELISA and immunohistochemistry (Desai & Wu, 2007). 
 
1.2.e MG and Oxidative Stress 
Oxidative stress is the imbalance between reactive oxygen species (ROS) production and 
antioxidant defense mechanisms in the body, caused by either excess free radical or ROS 
generation or impaired anti-oxidant enzymes. Free radicals are atoms or molecules with an 
unpaired electron in the outer orbit. Oxygen derived free radicals such as superoxide anion, 
hydroxyl radical, and non-radicals such as hydrogen peroxide that do not have an unpaired 
orbiting electron, are known as reactive oxygen species (ROS) (Desai & Wu, 2008). ROS are 
chemically highly reactive. 
The role of MG (Fig 1-6) in inducing oxidative stress in various cell types is well known. 
MG activates several pathways to increase oxidative stress. MG, both directly and via AGEs 
formation, increases the activity of p38 MAPK and expression of JNK. The increased activity of 
these enzymes increases the proinflammatory cytokines, such as interleukin-1β, interleukin 6, 
interleukin 8 and tumor necrosis factor (Kikuchi et al., 1999).  MG has also been shown to 
increase the superoxide anion, hydrogen peroxide and peroxynitrite formation, and prooxidant 
enzyme activity such as NADPH oxidase in various cell types such as VSMCs, endothelial cells, 
rat kidney mesangial cells, rat hepatocytes, platelets, SH-SY5Y neural cells. Incubation of 
VSMCs with 25 mM glucose or fructose for 3 h increases MG production 3.5 or 3.9 fold, 
respectively, and increases oxidative stress (Dhar et al., 2008). Excess superoxide anion so 
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formed can react with nitric oxide (NO) to form peroxynitrite which is a strong oxidant and 
nitrating agent (Takahashi et al., 2010; Dhar et al., 2008; Chen & Wu, 2008). 
MG can also increase oxidative stress by reducing antioxidants such as glutathione 
peroxidase, glutathione reductase and GSH. Glutathione peroxidase detoxifies hydrogen 
peroxide to water with the help of GSH, which is converted to reduced glutathione and then back 
to GSH with the help of glutathione reductase. Thus, reduced availability of anti-oxidants 
impairs MG detoxification and begins a cycle which further causes oxidative damage (Blakytny 
and Harding, 1992; Paget, 1998). MG-modified albumin treatment in monocytes resulted in 
increased ROS production, thus suggesting that MG, by activating monocytes, induced 
apopotosis of neutrophils, caused platelet–neutrophil aggregation, then thrombosis and 
inflammation (Desai & Wu, 2008). 
The major source of energy production and major site of ATP in the cells is the 
mitochondrion, which is also a major source of free radical generation especially superoxide 
anion. The intracellular superoxide anion is formed when single electrons escape the 
mitochondrial chain reaction, mainly from complex I and complex III and interact with 
molecular oxygen to form superoxide anion. In in vitro studies, MG has been shown to increase 
superoxide anion production. Rat aortic VSMCs treated with MG (30 µM) significantly 
increased superoxide anion production, which was prevented by the AGEs breaker, alagebrium 
(50 µM) (Chang et al., 2005; Wang et al., 2008b). Recently, we have shown that VSMCs and 
endothelial cells treated with MG (30 – 100 µM) for 24 h significantly increased ROS production 
in a time dependent manner which was prevented by arginine (Dhar et al., 2012). 
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Figure 1-6: Mechanisms of MG induced oxidative stress. Adapted from Drug Metabol Drug 
Interact. 2008;23(1-2):151-73. 
MG induces oxidative stress through multiple mechanisms and pathways as shown in the figure.  
Abbreviations: AGEs, advanced glycation end products; GSH, reduced glutathione; GSH-Px, 
glutathione peroxidase; GSH-Red, glutathione reductase; GSSG, oxidized glutathione; H2O2, 
hydrogen peroxide; ICAM-1, intercellular adhesion molecule-1; IFNγ, interferon γ; IL-1, 
interleukin-1; JNK, JUN N-terminal kinase; MG, methylglyoxal; NF-κB, nuclear factor-kappaB; 
NO, nitric oxide; O2
•-
, superoxide anion; ONOO
−
, peroxynitrite; p38 MAPK, p38 mitogen 
activated protein kinase; RAGE, receptor for advanced glycation endproduct; SOD, superoxide 
dismutase; VCAM 1, vascular cell adhesion molecule 1. 
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In in vivo studies the effect of MG on oxidative stress is associative. For example, we 
have shown that elevated plasma and aortic MG levels in the aorta of 13 week old SHR with 
elevated blood pressure is associated with increased superoxide anion levels and significantly 
reduced GSH levels, and glutathione peroxidase and glutathione reductase activities, compared 
to age-matched WKY rats. In diseases such as diabetes and hypertension, the elevation of MG 
levels is associated with increased oxidative stress (Wang et al., 2005). MG through AGEs 
formation can also cause oxidative stress. The excess of CEL, CML, and argpyrimidine formed 
by reaction of MG with lysine and arginine, are associated with oxidative stress. These AGEs 
and glycated proteins induce oxidative stress through production of cytokines and growth 
factors. Moreover, AGEs interact with the receptor for AGEs (RAGE) to induce oxidative stress 
in various cell types such as VSMCs, endothelial cells and phagocytes. AGE-RAGE interaction 
in the endothelial cells increases NF-κB activity to increase oxidative stress (Desai & Wu, 2008). 
 
1.2.f MG and Endothelial Dysfunction 
L-arginine (L-Arg), but not D-arginine (D-Arg), is a substrate for nitric oxide synthase 
(NOS), which catalyzes the formation of nitric oxide (NO) and L-citrulline (Palmer et al., 1988). 
There are three isoforms of NOS, endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal 
NOS (nNOS) (Moncada et al., 1991). eNOS is mainly found in the endothelial cells and 
mediates endothelium-dependent agonist induced vessel relaxation (Moncada et al., 1991). 
Reduced production or availability of NO is a common feature of endothelial dysfunction (De 
Vriese et al., 2000; Potenza et al., 2009), which is commonly defined as reduced endothelium-
dependent vascular relaxation, and is a feature of aging, as well as diabetes, atherosclerosis, 
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hypertension and several other conditions (Berkowitz et al., 2003; Zhanget al., 2001). Arginase 
is an enzyme of the urea cycle that converts L-Arg, but not D-Arg, to urea and ornithine. There 
are two isoforms, arginase I and arginase II (Haraguchi et al., 1987; Morris et al., 1997). 
Arginases are expressed in the endothelium (Wei et al., 2000) and can cause endothelial 
dysfunction (Zhang et al., 2001; Berkowitz et al., 2003). High glucose (25 mM) has been shown 
to increase arginase I activity, but not protein expression, in bovine coronary endothelial cells, 
and arginase I is increased in the aorta of streptozotocin diabetic rats (Romero et al., 2008), 
causing endothelial dysfunction (Ishizaka et al., 2007; Romero et al., 2008).  
We have recently shown that in cultured rat aortic and human umbilical vein endothelial 
cells MG and high glucose reduced basal and bradykinin-stimulated NO production, cyclic 
guanosine monophosphate levels, and serine-1177 phosphorylation and activity of eNOS without 
affecting threonine-495 and Akt phosphorylation, and total eNOS protein (Dhar et al., 2010b). 
Evidently, safe and specific MG scavengers have the potential to prevent several different 
pathological conditions such as endothelial dysfunction and AGEs formation. Currently, there is 
a lack of safe and specific MG scavengers. Several investigators have used different compounds 
as MG scavengers, which have other actions and thus are non-specific and can even produce 
toxicity. These compounds include aminoguanidine (Brownlee et al., 1986; Edelstein et al., 
1992). 
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Figure 1-7. Mechanism of nitric oxide mediated endothelium-dependent relaxation and 
endothelial dysfunction. Adapted from Biochem Pharmacol. 1989;38(11): 709-15.  
 
The figure (Fig 1-7) shows an endothelial cell and the adjacent VSMC. Stimulants like 
shear stress, bradykinin, insulin and vascular endothelial growth factor (VEGF) activate eNOS 
by causing an increase in intracellular calcium (Ca
2+
) and produce NO from the substrate L-Arg. 
NO diffuses to the VSMC, activates soluble guanylate cyclase (sGC), increases cyclic guanosine 
monophosphate (cGMP), reduces intracellular calcium and causes relaxation (Evora and Nobre, 
1999). Under pathological conditions like diabetes and hypertension, increased superoxide anion 
(O2•­) is produced, mainly from NADPH oxidase, which reacts with NO and forms peroxynitrite. 
This in turn reduces the bioavailability of NO and causes endothelial dysfunction. Reduced 
eNOS activity can also cause reduced NO production (Endemann and Schiffrin, 2004). 
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1.2.g MG Scavengers 
The MG scavengers available are also known as anti-MG or anti-AGE and are usually 
non-specific and have multiple effects, which limits their efficacy. Some of the common MG 
scavengers are aminoguanidine, metformin, N-acetyl cysteine, alagebrium and arginine.  
Aminoguanidine  
Aminoguanidine (AG) is the most commonly used MG scavenger and AGEs formation 
inhibitor (Brownlee et al., 1986). It reacts with the carbonyl group of glucose and prevents it 
from reacting with proteins and thus prevents AGEs formation. It also neutralizes reactive 
aldehydes such as MG, glyoxal and 3-DG which are the major precursors of AGEs formation, 
thus acting as a scavenger (Brownlee et al., 1986; Edelstein et al., 1992).  Aminoguanidine is a 
hydrazine derivative like hydralazine and has many properties similar to hydrazine (Nilsson, 
1999). AG is non-specific and besides acting as an AGEs inhibitor and MG scavenger it has 
other effects as well. AG prevents NO and MG production in the body by inhibiting NOS, which 
catalyzes the conversion of L-Arg to NO (Moncada et al., 1991), and SSAO, an enzyme which 
catalyzes the conversion of aminoacetone to MG, respectively. AG prevents deamination of 
diamines such as histamine by potently inhibiting diamine oxidase, thereby raising histamine 
concentration (Schuler 1952; Evy et al., 1956). AG increases the synthesis of polyamines by 
binding to the enzyme S-adenosylmethionine decarboxylase (Stjernborn & Persson, 1993).  AG 
can cause vitamin B6 deficiency by binding to pyridoxal, leading to its adverse effects (Miyata & 
Van, 2003). AG has an inhibitory effect on AGEs formation as well as other mixed effects as 
shown in various in vitro and in vivo studies (Brownlee et al., 1986; Edelstein et al., 1992; 
Sajithlal et al., 1994; Conman et al., 1998). The in vivo dose of AG used in rodents ranges from 
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25 mg/kg/day (Brownlee et al., 1986; Seyer-Hansen et al., 1991) to 100 mg/kg/day (Inoue et al., 
1998). Besides acting as an anti-oxidant in vitro, AG lowers total cholesterol, LDL and 
triglycerides in diabetic subjects. Studies have shown that AG reduces diabetes related 
complications like neuropathy, retinopathy and nephropathy in diabetic animal models. 
However, in clinical trials AG has shown safety concerns and unexpected results. In a clinical 
trial conducted on 690 patients with diabetic nephropathy, AG did not prevent the renal damage 
progression and did not show a statistically significant difference compared to the placebo group, 
apart from lowering serum creatinine (Bolton et al., 2004; Freedman et al., 1999). AG being like 
hydrazine, has many toxic effects. For example it may have effects like, antinuclear cytoplasmic 
antibody production, drug induced systemic lupus erythematosus and abnormal liver function. 
The patients treated with AG have flu-like symptoms, vasculitis and anaemia, thus limiting its 
therapeutic potential (Freedman et al., 1999). Moreover, AG through hydrogen peroxide 
formation in the presence of Fe
3+ 
can also cause DNA damage (Suji & Sivakami, 2006). 
Metformin 
Metformin is a commonly used drug for type 2 diabetes and comes under the class of 
biguanides. Chemically it is dimethylbiguanide and it is also a MG scavenger and AGEs 
formation inhibitor (Beisswenger et al., 1999). One study has shown that metformin scavenges 
MG by neutralizing it, via its guanidine group, which actually binds to MG and forms the 
inactive product triazepinone (Beisswenger & Ruggiero-Lopez, 2003; Ruggiero-Lopez et al., 
1999; Baynes, 1991; Ota et al., 2007). Furthermore, metformin by increasing MG detoxification 
also reduces MG levels. Due to its MG scavenging effect, type 2 diabetes patients treated with 
high doses of metformin, ranging from 1,500 to 2,500 mg have significantly reduced MG levels 
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(Beisswenger et al., 1999). We have also shown that SD rats fed with a high fructose diet have 
significantly high levels of MG in the plasma, hydrogen peroxide and MG-derived AGE, CEL, 
in the aorta, and high BP, which were attenuated by metformin (Wang et al., 2008) Also, in an 
another study diabetic rats treated chronically with metformin had reduced AGEs formation in 
the lens, kidney and nerves (Tanaka et al., 1999). However, its use as a MG scavenger and AGEs 
inhibitor is limited due to its multiple effects, and it is currently used for type 2 diabetes as an 
insulin sensitizing drug. 
N-acetyl cysteine  
N-acetyl cysteine (NAC) is a well-known anti-oxidant and a MG scavenger (Millea, 
2009; Vasdev et al., 1998).  It is also known by other names such as acetylcysteine or N-acteyl- 
L-cysteine.  NAC is the acetyl derivative of the amino acid cysteine, containing a thiol group, 
and MG has high binding affinity for cysteine (Vasdev et al., 1998; Lauterberg et al., 1983). 
NAC can also increase GSH levels (Lauterberg et al., 1983), the prime MG scavenger and 
antioxidant (Jia et al., 2006; Millea, 2009; Vasdev et al., 1998); thereby further acting as a MG 
scavenger and an anti-oxidant.  It is also sold as a food supplement for protecting against liver 
abnormalities. It is clinically used in the management of acetaminophen overdose and cough 
(Millea, 2009; Lauterberg et al., 1983). 
Alagebrium (ALA) 
 Alagebrium (ALA), also known formerly as ALT 711, is 4, 5-dimethylthiazolium 
(Wolffenbuttel et al., 1998) (Fig 1-8). ALA is an AGEs breaker and a MG scavenger. It acts as 
an AGEs breaker by breaking the covalent cross-links and thus is belived to be more important 
compared to AGEs inhibitors which are ineffective against formed AGEs (Desai & Wu, 2007). 
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ALA also causes reduction in oxidative stress and profibrotic cytokines (Susic et al., 2004). 
Moreover, AGEs induced oxidative stress is inhibited by ALA (Vasan et al., 2001).  ALA has 
several beneficial actions on aging as well as on pathological conditions such as increased 
ventricular and arterial stiffness as observed in different animal models (Asif et al., 2000). ALA 
decreased ventricular stiffness and improved cardiac function in aged dogs treated with ALA for 
one month (Asif et al., 2000). ALA (10 mg/kg for 16 weeks) reduced oxidative stress and 
increased enzyme activity of glutathione peroxidase and superoxide dismutase in aging rats (Guo 
et al., 2009). Altered cardiac function was improved in older rhesus monkeys treated with ALA 
(Vaitkevicius et al., 2001). Clinical studies conducted on ALA showed it to be safe and revealed 
favourable results. ALA improved arterial compliance in a clinical study involving elderly 
patients with vessel stiffness, high systolic blood pressure and large artery compliance (Kass et 
al., 2001). In addition, other clinical studies showed that ALA reduced vascular fibrosis in 
elderly patients with systolic hypertension (Zieman et al., 2007) and decreased left ventricular 
mass in patients with diastolic heart failure (Little et al., 2005; Bakris et al., 2004). 
 
 
 
 
 
Figure 1-8 Chemical structure of alagebrium. 
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Increased DNA deletion, AGEs formation, reduced antioxidant capacity in aging heart 
and decreased superoxide dismutase activity and glutathione peroxidase activity in both aging 
heart and cardiomyocytes were all reversed on treatment with ALA, which also improved cardiac 
function (Guo et al., 2009). Furthermore, ALA does not inhibit thiamine diphosphokinase, which 
catalyses deamination of thiamine, and it therefore does not interfere with thiamine metabolism 
(Krautwald et al., 2011). 
ALA also has acute preventive effect against MG as shown in our study in cells and SD 
rats. In SD rats administered MG (tested after 6 h exposure to MG), ALA significantly 
attenuated increased MG levels in the plasma and different organs and also attenuated MG-
induced glucose intolerance. Moreover, ALA attenuated the increased MG levels in cells treated 
with MG, indicating its acute MG scavenging effect (Dhar et al., 2010). 
Arginine 
Arginine (Fig 1-9) is an amino acid and exists in two isomeric forms, L-Arg and D-Arg. 
L-arginine is a substrate for several enzymes including nitric oxide synthase (NOS), which 
converts it into NO and L-citrulline (Palmer et al., 1988). NO is a physiological mediator and a 
neurotransmitter with several physiological and pathological functions such as vascular and 
gastrointestinal smooth muscle relaxation, immune response, excessive vasodilation in septic 
shock etc (Moncada et al., 1991). The enzyme arginase uses L-arginine to produce ornithine and 
enable ammonia detoxification through the urea cycle (Haraguchi et al., 1987; Morris et al., 
1997; Morris, 2009). L-arginine, alongwith glycine, is also converted by arginine:glycine 
amidinotransferase to ornithine and guanidinoacetate, the latter is then metabolized to creatine 
(Levillain, 2012; Van Pilsum et al., 1972). This helps with Na/K ATPase activity, 
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neurotransmitter release and other functions in the central nervous system. The enzyme arginine 
decarboxylase uses L-arginine as a substrate to produce agmatine, which is further converted to 
putrescine and urea by agmatinase (Satriano, 2003; Grillo & Colombatto, 2004). Thus, L-
arginine is a part of several metabolic pathways. 
L-arginine supplements have been reported to be useful in various conditions (Coman et 
al., 2008; Tapiero et al., 2002) including in preterm infants (Wu et al., 2004). It has been used 
for improving endothelium-dependent vasodilation in humans with hypercholesterolemia 
(Creager et al., 1992; Clarkson et al., 1996) and to lower the blood pressure in hypertension 
(Dong et al., 2011; Rajapakse et al., 2008). It was shown to reduce AGEs in diabetic rats (Pai et 
al., 2010). D-arginine has been reported to have no significant toxicity in mice besides having 
some non-specific effects (Navarro et al., 2005). 
 
 
 
 
Figure 1-9 Chemical structure of L-arginine. 
 
Due to its high affinity for MG, arginine can have great value as a safe MG scavenger.  
Since L-Arg is a substrate for 5 different enzymes, D-Arg can be a more specific and effective 
MG scavenger.  
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CHAPTER 2 
 
HYPOTHESIS AND OBJECTIVES 
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2.1 Rationale for hypothesis 
MG is a reactive aldehyde produced mainly from glucose and fructose in the body. 
Plasma MG levels are elevated in conditions of hyperglycemia. An excess of MG, not degraded 
by the glyoxalase enzymes, reacts with exposed arginine, lysine and cysteine residues of proteins 
and enzymes and causes pathology. An ongoing investigation of proteins, enzymes and other 
macromolecules modified by MG is revealing the pathological effects of excess MG. For 
example we have recently shown that treatment of cultured rat aortic and human umbilical vein 
endothelial cells with MG or high glucose reduces eNOS activity and causes endothelial 
dysfunction (Dhar et al., 2010b). We have also shown that administration of MG for 4 weeks as 
a continuous infusion by a subcutaneous minipump induces features of type 2 diabetes in male 
SD rats (Dhar et al., 2011).  
Dr Wu’s lab investigated two animal models which have hypertension, the SHR and high 
fructose diet fed rats (Hwang et al., 1987), and found that the plasma and tissue levels of MG 
were significantly elevated by 2-4 fold in both of these animal models, compared to their 
respective control groups (Wang et al., 2005; Wang et al., 2008). However, elevated plasma and 
tissue levels of MG under hypertensive condition were associative findings in these studies and 
did not establish a cause-effect relationship. In order to establish a direct role of MG in causing 
hypertension, it is necessary to administer MG exogenously in healthy animals and observe its 
effect on the BP and on body systems known to regulate the BP such as the RAAS and the 
sympathetic nervous system. The in vivo effects of exogenously administered MG have not been 
studied to evaluate its role in the pathogenesis of hypertension. Based on this rationale I used 
exogenous administration of MG in normal male SD rats in this project. The results obtained by 
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exogenous administration of MG can be corroborated by studies in which endogenous 
production of MG is increased. One way of increasing endogenous MG production in the body is 
by feeding animals with a high carbohydrate diet, either a high glucose or a high fructose diet, 
both of which are known precursors of MG formation (Dhar et al., 2008). Moreover, high 
carbohydrate diet fed animals are known to develop hypertension (Hwang et al., 1987; Kaufman 
et al., 1991; Nakagawa et al., 2006; Sanchez-Lozada et al., 2007; Tom et al., 2011; Wang et al., 
2008). Therefore, I also used high fructose diet fed male SD rats in my project to study the role 
of endogenous MG in hypertension and on the body systems regulating the BP such as the 
RAAS.  
The effects of an exogenous or endogenous compound in the body can be additionally 
confirmed by the use of co-treatment with a known inhibitor of the compound, which should 
attenuate or prevent the effects of the compound. Studies involving MG become limited by lack 
of availability of specific MG scavengers. Some of the MG scavengers used by researchers 
include aminoguanidine (Brownlee et al., 1986; Edelstein et al., 1992), N-acetyl cysteine (Jia et 
al., 2006; Millea, 2009; Vasdev et al., 1998), metformin (Beisswenger et al., 1999; Beisswenger 
& Ruggiero-Lopez, 2003; Ruggiero-Lopez et al., 1999; Baynes, 1991; Ota et al., 2007) and 
alagebrium (Dhar et al., 2010). However, none of these are specific as MG scavengers, and 
aminoguanidine also has toxic effects (Freedman et al., 1999; Suji & Sivakami, 2006). One of 
the aims of my project was to identify a novel specific and safe MG scavenger. MG has great 
affinity for arginine (Takahashi ,  1977; Lo TW et al.,  1994). As discussed in the introduction, 
L-arginine is a substrate for at least five different enzymes in the body so it can have other 
effects when it is used as a MG scavenger. On the other hand D-arginine is not a substrate for 
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those enzymes and it may act specifically as a MG scavenger only with no or minimal other 
effects. It is also possible that L-arginine, besides scavenging MG can be an attractive oral 
supplement due to its reported beneficial effects on endothelial dysfunction and the BP (Creager 
et al., 1992; Clarkson et al., 1996; Dong et al., 2011; Rajapakse et al., 2008). 
Based on the above rationale the following hypotheses were formed: 
 
2.2 Hypotheses:  
(i) A pathological elevation of methylglyoxal levels in the body, resulting 
from exogenous administration, or produced from a high fructose diet, 
upregulates the renin angiotensin aldosterone system and causes 
hypertension.  
(ii) Arginine can scavenge methylglyoxal and attenuate its deleterious 
effects on endothelial function and oxidative stress.   
 
2.3 Objectives and experimental approach: 
 
2.3.a To investigate whether exogenous MG, administered by a continuous infusion for 4 
weeks, is a causative factor in the pathogenesis of hypertension: A study of the underlying 
signaling pathways and molecular mechanisms in Sprague-Dawley rats and cultured cells. 
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 I performed experiments to determine whether MG is one of the causative factors in the 
development of hypertension. Since the RAAS plays a major role in the regulation of BP, I 
focused my attention on the RAAS. Ang II acts on VSMC AT1 receptors to cause 
vasoconstriction, therefore I also looked at the expression of AT1 receptors. Since Ang II also 
facilitates peripheral noradrenergic neurotransmission and releases catecholamines from the 
adrenal medulla, I also determined the expression of adrenergic α1D receptors.  
The effects of MG, and alagebrium, a MG scavenger, on the RAAS and the BP were 
investigated in 12 week old male SD rats.  SD rats were treated with a continuous infusion of 
MG with a subcutaneously implanted minipump for 4 weeks. Organs / tissues and cultured 
VSMCs were used for molecular studies. HPLC was used to measure MG levels, western 
blotting was used to measure proteins for adrenergic α1D receptor, AT1 receptor, angiotensin, 
renin, Erk 1/2  (p-Erk 1/2), NFATc and NFkB. Q-PCR was used to measure mRNA levels for 
α1D receptor, AT1 receptor, angiotensin and renin in cultured cells, kidney and aorta of MG 
treated rats. Possible mechanisms were explored through gene silencing of angiotensinogen and 
RAGE. 
 
2.3.b To investigate the effects of a high fructose diet, a precursor for MG formation, on the 
pathogenesis of hypertension and its attenuation by a MG scavenger: A study of the 
underlying signaling pathways and molecular mechanisms in Sprague-Dawley rats.  
High fructose corn syrup and sugar are the main ingredients of a high carbohydrate diet, 
which is believed to be the root cause of the current epidemic of obesity, type 2 diabetes and the 
associated cardiovascular pathology. The aim of my study was to investigate whether MG is a 
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mediator of fructose-induced hypertension and the underlying molecular mechanisms, since 
fructose is a known precursor of MG generation (Dhar et al., 2008). Male SD rats were treated 
with a high fructose diet (60% of total calories) for 16 weeks. The thoracic aorta and cultured 
VSMCs were used to study the signaling pathways and the molecular mechanisms. HPLC was 
used to measure MG and GSH levels, western blotting was used to measure proteins for 
adrenergic α1D receptor, AT1 receptor, angiotensin, renin , Erk 1/2  (p-Erk 1/2 ) and NFATc. Q-
PCR was used to measure mRNA levels for α1D receptor, AT1 receptor, angiotensin, renin in the 
kidney and the aorta of fructose treated rats. 
 
2.3.c To investigate whether arginine can attenuate methylglyoxal- and high glucose-
induced endothelial dysfunction and oxidative stress in rat isolated aortic rings and 
cultured cells. 
Specific and safe MG scavengers are not available. Since MG has great affinity for 
arginine (Takahashi,  1977; Lo TW et al.,  1994), I investigated whether L-arginine and D-
arginine can attenuate MG and high glucose-induced endothelial dysfunction and oxidative 
sress. Aortic rings isolated from 12 week old male SD rats were used for contractility studies. 
Cultured human umbilical vein endothelial cells (HUVECs) and VSMCs were used to define 
molecular pathways and mechanisms. HPLC was used to measure MG levels and western 
blotting was used to measure proteins for NF-κB, NADPH oxidase 4, arginase I and II. 
Dicholorofluorescein (DCF) probe was used to measure oxidative stress. Immuostaining was 
used to measure MG-induced AGE (CEL). 
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3.1 Animals 
Male 11-week old Sprague-Dawley rats from Charles River Laboratories (Saint-Constant, 
Quebec, Canada) were used according to a protocol approved by the Animal Care Committee at 
The University of Saskatchewan, following guidelines of the Canadian Council on Animal Care. 
After one week of acclimatization, the rats were anesthetized with an inhalation of isoflurane 
(Forane, 4% in oxygen), delivered through a precision vaporizer and circle absorption breathing 
system (Ohio, 30/70 Proportioner Anesthesia Machine, Madison, Wisconsin). When anesthesia 
reached sufficient depth as determined by the absence of the leg flexor response and the eyelid 
reflex, the thorax was quickly opened by a midline incision and the rat was killed by cutting open 
the heart and causing exsanguination, an accepted method of euthanasia by the Animal Care 
Committee. The aorta was quickly removed without damaging the endothelium and placed in a 
beaker filled with Kreb’s solution and bubbled with 95% O2 + 5% CO2.  
In one separate batch of 28 male 12 week old SD rats a subcutaneous mini-osmotic pump 
(Alzet® 2ML4) (Durect Corporation, Cupertino, CA, USA) was implanted to deliver either 
saline (0.9%) or MG (24 mg/day) by continuous infusion for 28 days. The rats were randomly 
divided into the following treatment groups (n = 7 in each group): 1. Control (0.9% saline by 
pump), 2. MG (24 mg/day by pump), 3. MG + alagebrium (ALA, 30 mg/kg/day in drinking 
water), 4.  ALA (30 mg/kg/d in drinking water) + 0.9% saline by pump. In a second batch of 24 
male 12 week old Sprague-Dawley rats a different MG scavenger, aminoguanidine, had to be 
used due to unavailability of ALA. The following treatments were provided to 4 groups (n = 6 
each): 1. Control (0.9% saline by pump), 2. MG (24 mg/day by pump), 3. MG + aminoguanidine 
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(AG, 100 mg/kg/day in drinking water), 4.  AG (100 mg/kg/d in drinking water) + 0.9% saline 
by pump 
For high fructose diet study 32 male 5 week old Sprague-Dawley rats were divided into 
the following groups (n = 8 in each group): 1. Control chow, 2. High fructose (60% in diet), 3. 
High fructose + metformin (500 mg/kg/day in drinking water), 4. Metformin (500 mg/kg/day in 
drinking water  + control chow). The treatments were for 16 weeks.  
At the end of study fructose treated (16 weeks) and MG pump treated (28 days) rats were 
anaesthetized with sodium pentobarbital (60 mg/kg body weight) which was given 
intraperitoneally. BP was again measured by carotid artery cannulation for 30 min. Blood was 
collected from the carotid artery and plasma was separated from the samples after centrifugation 
at 12,000 g for 10 min at 4°C. Tissues cleaned in ice-cold phosphate buffer saline were 
immediately frozen in liquid nitrogen and stored at -80°C until processing. 
 
3.2 Cell culture 
Rat thoracic aortic smooth muscle cell line (A-10 cells) was obtained from American 
Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS) at 37° C in a humidified 
atmosphere of 95% air and 5% CO2, as described in previous studies from our lab (Dhar et al., 
2008). A-10 cells were seeded either in 100 mm dishes for MG measurement or in 96-well plates 
for other assays, with an equal amount of cells (10
6
/mL) in each well, and cultured to confluence. 
For immunocytochemistry staining, cells were seeded on cover glass slides (2×10
6
/mL). Cells 
were starved in FBS-free DMEM for 24 h before exposure to different metabolic precursors.  
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Human umbilical vein endothelial cells from American Type Culture Collection (ATCC, 
Manassas, VA, USA) were cultured in Kaighn’s F12K medium containing 10% fetal bovine 
serum (FBS), 0.1 mg/mL heparin and 0.03-0.05 mg/mL endothelial cell growth supplement 
(Dhar et al., 2010b).  
 
3.3 Methlyglyoxal assay 
MG was measured by a specific and sensitive HPLC method as described previously 
(Dhar et al., 2009). MG was derivatized with o-phenylenediamine (o-PD) to specifically form 2-
methylquinoxaline. The samples were incubated in the dark for 24 h with 0.45 N perchloric acid 
(PCA) and 10 mM o-PD at room temperature. Samples were centrifuged at 12000 rpm for 10 
min. 2-methylquinoxaline and quinoxaline internal standard (5-methylquinoxaline) were 
quantified on a Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada) via 
Nova-Pak® C18 column (3.9×150 mm, and 4 μm particle diameter, Waters Corporation, 
Milford, MA, USA) (Dhar et al., 2009). 
 
3.4 Western blotting 
Cell lysates were prepared as described earlier (Dhar et al., 2010b; Dhar et al., 2011)  and 
the protein concentration in the supernatant was determined by the BCA protein assay (Sigma-
Aldrich Canada Co., Oakville, ON, Canada). Aliquots of cell lysates (40-50 μg of protein each) 
were separated on 6-10% SDS-PAGE, electrotransferred to a polyvinylidene difluoride (PVDF) 
membrane (Bio-Rad Laboratories Canada Ltd., Mississauga, ON, Canada), blocked with 5% 
nonfat milk in TBS-Tween buffer for 2 h at room temperature, and incubated overnight at 4° C 
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with the primary antibodies to arginase I, arginase II, NADPH oxidase 4 (NOX4), AT1 receptor 
(AT1R), α1D receptor (α1DR), renin, angiotensin, ACE, (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA), receptor for AGEs (RAGE), nuclear factor κB (NF-κB) (Abcam, Cambridge, 
MA, USA), and anti-β-actin (diluted 1:1000) (Sigma-Aldrich Canada Ltd., Mississauga, ON, 
Canada) followed by incubation with horse radish peroxidase conjugated secondary antibodies 
(Life Science, Hercules, CA, USA) (diluted 1:3000) for 2 h at room temperature and then with 
horseradish peroxidase conjugated secondary antibody (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA) for 1 h at room temperature. After extensive washing, the immunoreactive 
proteins were detected with an Enhanced Chemiluminescence Detection System (ECL; 
Amersham Biosciences Corp., Piscataway, NJ, USA) (Dhar et al., 2010b; Dhar et al., 2011).  
 
3.5 Real time Quantitative PCR (RT-PCR) 
Total RNA from the cultured cells, kidney and aorta was isolated using RNA isolation kit 
(Qiagen, Germantown, MD, USA). The pre-designed primers for angiotensin, AT1R, α1DR, 
renin, aldosterone receptor (MR) and RAGE were purchased from Qiagen, (Germantown, MD, 
USA). The real-time PCR was performed in an iCycler
 
iQ apparatus (Life Science, Hercules, 
CA, USA) associated with the
 
ICYCLER OPTICAL SYSTEM software (version 3.1) using 
SYBR Green
 
PCR Master Mix (Bio-Rad Laboratories Canada Ltd., Mississauga, ON, Canada). 
 
3.6 Arginase activity assay 
Arginase activity was measured using an arginase assay kit (BioAssay Systems, 
Hayward, CA, USA). Arginase catalyses the conversion of arginine to orinithine and urea. 
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Briefly cell lysates were mixed with substrate arginine buffer and incubated for 2 h. Urea reagent 
was added to stop the reaction and optical density (OD) was measured at 430 nm. 
 
3.7 Measurement of reactive oxygen species 
Confluent cells were loaded with a membrane-permeable, nonfluorescent probe 2’,7’-
dichlorofluorescin diacetate (CM-H2DCFDA, 5 μM) for 2 h at 37° C in FBS-free medium in the 
dark. The cells treated with MG (30 μM) or glucose (25 mM) for 24 h were assayed for 
fluorescent oxidized dichlorofluorescein (DCF) as an indicator of production of ROS as 
described earlier (Dhar et al., 2008; Dhar et al., 2010b). The protein content of the homogenate 
was measured by BCA Protein assay (Bio-Rad, Hercules, CA, USA).  
 
3.8 Immunocytochemistry  
A-10 cells were seeded on glass cover slips followed by incubation with different test 
compounds for 24 h, and subjected to staining for the MG-induced AGE, Nε-carboxyethyl lysine 
(CEL). As described previously (Dhar et al., 2008; Dhar et al., 2011), the treated cells were fixed 
in 4% paraformaldehyde for 30 min at room temperature and washed twice with 0.01 N 
phosphate buffered saline (PBS). After permeation with 0.1% Triton X-100 for 5 min and two 
washes with PBS, the cells were incubated with normal goat serum (diluted 1:30 in 0.1 N PBS) 
for 1 h to block non-specific binding sites. After shaking off the goat serum the slides were 
incubated with the CEL antibody (1:100; a generous gift from Novo Nordisk, A/S, Denmark) 
overnight at room temperature. Cells were washed twice in PBS (0.01 N) for 5 min and 
incubated with secondary fluorescein isothiocynate (FITC) conjugated anti-CEL antibody 
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(Molecular Probes) for 2 h. After washing thrice with PBS the slides were mounted in 
glycerol:PBS (3:7), coverslipped and observed under a fluorescence microscope. Staining 
intensity was quantified using the Metapmorph image analysis software (v. 7, Molecular 
Devices). Slides from four different experiments were analyzed with 5 fields per slide observed 
and averaged. 
 
3.9 Isometric tension studies on aortic rings 
A group of 24 SD rats was used. Isometric tension studies were carried out on rat aortic 
rings as described (Dhar et al., 2010b). Briefly, 3-4 mm thoracic aortic rings from the rat aorta 
were mounted under a 2 g load in four separate 10
 
mL organ baths containing Krebs solution 
with 5 mM glucose, maintained at 37° C and bubbled with 95% O2 + 5% CO2. After a 90 min 
equilibration period the rings were pre-contracted with phenylephrine (1 µM) and cumulative 
concentration-dependent relaxation in response to acetylcholine (ACh) was obtained before 
(Control) and 2 h after incubation with either glucose (25 mM) or MG (100 μM) (Dhar et al., 
2010b), or the nitric oxide synthase inhibitor, Nω-nitro-L-arginine methyl ester (L-NAME, 10 
μM). In initial experiments the responses to ACh were repeated before and 2 h after incubation 
with normal Krebs solution to confirm reproducibility of responses to ACh. Some sets of rings 
were co-incubated with either L-Arg (300 μM) or D-Arg (300 µM) for 2 h. Treatment with each 
compound was tested in rings from at least 5 different rats. Isometric
 
tension was measured with 
isometric force transducers with the ‘Chart’ software and Powerlab equipment (AD Instruments 
Inc., Colorado Springs, CO, USA).  
 
51 
 
3.10 Plasma assays 
 Assay kits for quantitative determination of  plasma renin (AnaSpec, Fremont, CA, 
USA), angiotensin II (Biovendor LLC, Candler, NC, USA), aldosterone (Cayman Chemical Co., 
AnnArbor, MI, USA), and catecholamines (Rocky Mountain Diagnostics Inc., Colorado Springs, 
CO, USA) were used according to the manufacturer’s instructions. 
 
3.11 Short interfering (siRNA) transfection  
In a six well tissue culture plate, 2 x 10
5
 cells per well were grown in 2 mL antibiotic-free 
normal growth medium supplemented with FBS. Cells were incubated at 37° C in a CO2 
incubator until 60-80% confluent. For each transfection, 2-8 μL of siRNA duplex (Solution A, 
0.25-1 μg or 20-80 pmols siRNA) was diluted with 100 μL siRNA transfection medium (Cat # 
sc-36868, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). For each transfection, 2-8 μL 
of siRNA transfection reagent (Solution B, Cat # sc-29528, Santa Cruz Biotechnology Inc.) was 
diluted with 100 μL siRNA transfection medium (Cat # sc-36868). siRNA duplex solution 
(Solution A) was directly added to the dilute transfection reagent (Solution B) using a pipette. 
The solution was mixed gently by pipetting up and down, following which it was incubated for 
15-45 min at room temperature. The cells were washed once with 2 mL of siRNA transfection 
medium (Cat # sc-36868). For each transfection, 0.8 mL siRNA transfection medium was added 
to each tube containing the siRNA transfection reagent mixture (Solution A + Solution B). After 
gentle mixing the mixture was added to the washed cells, and incubated for 5-7 h at 37° C in a 
CO2 incubator. After the required incubation, 1 mL of normal growth medium containing 2 times 
the normal serum and antibiotics concentration (2x normal growth medium) was added without 
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removing the transfection mixture. The cells were additionally incubated for another 18-24 h. 
After 24 h, the medium was aspired and replaced with fresh 1x normal growth medium. The cells 
were assayed 48-72 h later after the addition of fresh medium. 
 
3.12 Measurement of reduced glutathione (GSH) 
The reduced glutathione (GSH) levels in tissues was determined by derivation with 5, 5'-
dithio-bis (2-nitrobenzoic acid), and reverse-phase HPLC using ultra-violet detection (Kamencic 
et al, 2000). An equal volume of 10% 5-sulfosalicylic acid containing 0.2 mM EDTA was added 
to the tissue or cell homogenate to precipitate the proteins. After centrifugation at 10,000 g for 15 
min the supernatants were collected for GSH analysis. The reaction mixture was made by mixing 
0.5 mL 50 mM Tris–HCl buffer (pH 8.9), 0.13 mL sample or standard, 0.02 mL internal standard 
[400 µM D(2)-penicillamine in cold 5% sulfosalicylic acid containing 0.1 mM EDTA], and 0.35 
mL 10 mM 5,5-dithiobis(2-nitrobenzoic acid) made in 0.5 mM K2HPO4 (pH 7.2). After 5 min 
incubation, the mixture was acidified with 0.05 mL 7 M H3PO4. 50 µl of the mixture was 
injected for elution at 37°C using a Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, 
ON, Canada) via Nova-Pak® C18 column (150 x 4.6 mm, 4 μm particle diameter, Waters 
Corporation, Milford, MA, USA). The mobile phase was made by mixing 12.5% methanol (v/v) 
and 100 mM KH2PO4 (pH 3.85). The flow rate was set at 1.1 mL/min. Sulfhydryl–DTNB 
derivatives were detected by ultraviolet absorbance at 330 nm. Standards contained L-cysteine, 
cysteinyl glycine, glutathione, and DL-homocysteine.  
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Publications and their relation to the thesis 
The results of this thesis have been published as three manuscripts.  
Chapter 4 describes the effects of exogenously administered MG on the RAAS and BP. 
These experiments were carried out to investigate our hypothesis (i) that a pathological elevation 
of MG, administered exogenously or produced from a high fructose diet in the body, causes 
hypertension. The experimental protocols were designed in accordance with objective 2.2.a 
described in chapter 2. The roles of the authors listed in this manuscript were as follows: Indu 
Dhar – I performed all the experiments, helped to design the experimental protocols and 
suggested some ideas to the supervisor. I wrote the first draft of the manuscript and revised the 
manuscript as suggested by the supervisor, co-supervisor and peer reviewers. Arti Dhar – a 
senior graduate student and a postdoctoral fellow taught me some of the techniques and 
supervised me in the lab at the beginning. Lingyun Wu – my co-supervisor suggested some 
ideas, and provided critical inputs towards my work, manuscript and discussions. Kaushik Desai 
– my supervisor suggested the idea for the work and provided critical inputs towards my work, 
manuscript and discussions. 
Chapter 5 describes the effects of a high fructose diet and the role of endogenously 
produced MG on the RAAS and BP. These experiments were carried out to investigate our 
hypothesis (i) that a pathological elevation of methylglyoxal, administered exogenously or 
produced from a high fructose diet in the body, causes hypertension. After showing the role of 
exogenous MG in up regulating the RAAS and increasing the BP, the next logical step was to see 
if endogenously produced MG had similar effects on the RAAS and the BP, as exogenously 
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administered MG. Fructose is a precursor for MG formation (Dhar et al., 2008) and a major 
component of the high carbohydrate diets in humans. High fructose diet is believed to be 
responsible for the current epidemic of type 2 diabetes and the associated cardiovascular 
conditions (Johnson et al., 2007; Selvaraju et al., 2012; Stanhope, 2012). Therefore, rats were 
fed a high fructose diet, which has been shown previously to generate increased MG (Wang et 
al., 2008). The experimental protocols were designed in accordance with objective 2.2.b 
described in chapter 2. The roles of the authors listed in this manuscript were as follows: Indu 
Dhar – I performed all the experiments, helped to design the experimental protocols and 
suggested some ideas to the supervisor. I wrote the first draft of the manuscript and revised the 
manuscript as suggested by the supervisor, co-supervisor and peer reviewers. Arti Dhar – a 
senior graduate student and a postdoctoral fellow taught me some of the techniques, and 
reviewed and suggested corrections for my manuscript. Lingyun Wu – my co-supervisor 
suggested some ideas, and provided critical inputs towards my work, manuscript and 
discussions. Kaushik Desai – my supervisor suggested the idea for the work and provided critical 
inputs towards my work, manuscript and discussions. 
Chapter 6 describes the effects of arginine in preventing or attenuating the deleterious 
effects of MG. These experiments were carried out to investigate our hypothesis (ii) that arginine 
can scavenge MG and attenuate its deleterious effects on endothelial function and oxidative 
stress.  One major problem we encountered in our project work was finding a specific, safe and 
effective MG scavenger to prevent its harmful effects. One of the principles of pharmacological 
experiments is to demonstrate that effects of a given agent A can be prevented by another agent 
B, which can be a specific antagonist, or a scavenger of agent A. This strategy is used to 
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establish a cause effect relationship and to discover new drugs. Since there are no safe and 
specific MG scavengers our intention was to determine whether arginine, an amino acid and a 
commonly used nutritional supplement, can act as an effective MG scavenger. This idea was 
based on the known affinity of arginine for MG (Takahashi, 1977). The experimental protocols 
were designed in accordance with objective 2.2.c described in chapter 2. The roles of the authors 
listed in this manuscript were as follows: Indu Dhar – I performed all the experiments and helped 
to design the experimental protocols. I wrote the first draft of the manuscript and revised the 
manuscript as suggested by the supervisor, co-supervisor and peer reviewers. Arti Dhar – a 
senior graduate student and a postdoctoral fellow taught me some of the techniques including 
isolated aortic ring experiments, and reviewed and suggested corrections for my manuscript. 
Lingyun Wu – my co-supervisor suggested some ideas, and provided critical inputs towards my 
work, manuscript and discussions. Kaushik Desai – my supervisor suggested the idea for the 
work and provided critical inputs towards my work, manuscript and discussions. 
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CHAPTER 4 
Methylglyoxal, a reactive glucose metabolite, increases renin 
angiotensin aldosterone and blood pressure in male Sprague-Dawley rats 
Indu Dhar, Arti Dhar, Lingyun Wu*, Kaushik M Desai* 
ID, AD, KD: Department of Pharmacology, College of Medicine, University of 
Saskatchewan, Saskatoon, Canada 
LW: Department of Health Sciences, Lakehead University, Thunder Bay, Canada 
& Thunder Bay Regional Research Institute, Thunder Bay, ON, Canada 
This chapter is “In Press” (DOI: 10.1093/ajh/hpt281) to be published soon in the 
American Journal of Hypertension  
Running title: Methylglyoxal and renin angiotensin system  
Non-standard abbreviations: AGEs - advanced glycation endproducts; ALA – alagebrium; Erk 
1/2 - extracellular signal related kinases 1/2; MG – methylglyoxal; NF-κB - nuclear factor kappa 
B; RAAS - renin angiotensin aldosterone system; RAGE - receptor for AGEs; VSMCs - vascular 
smooth muscle cells  
 
57 
 
4.1 Abstract 
The majority of people with diabetes develop hypertension, along with increased activity 
of the renin angiotensin system. Methylglyoxal, a reactive glucose metabolite, is elevated in 
diabetic patients. We investigated the effects of methylglyoxal, and alagebrium, a methylglyoxal 
scavenger, on the renin angiotensin system and blood pressure. Male Sprague-Dawley rats were 
treated with a continuous infusion of methylglyoxal with a minipump for 4 weeks. Organs / 
tissues and cultured vascular smooth muscle cells (VSMCs) were used for molecular studies. 
HPLC, Western blotting and Q-PCR were used to measure methylglyoxal, proteins and mRNA, 
respectively. siRNA for angiotensinogen and the receptor for advanced glycation endproducts 
(RAGE) were used to study mechanisms. Methylglyoxal treated rats developed a significant 
increase in blood pressure and plasma levels of aldosterone, renin, angiotensin and 
catecholamines. Methylglyoxal level, and protein and mRNA for angiotensin, AT1 receptor, 
adrenergic α1D receptor and renin were significantly increased in the aorta and/or kidney of 
methylglyoxal treated rats, a novel finding. Alagebrium attenuated the above effects of 
methylgloyxal. Treatment of cultured VSMCs with methylglyoxal or high glucose (25mM) 
significantly increased cellular methylglyoxal, and protein and mRNA for NF-κB, angiotensin, 
AT1 and α1D receptors, which were prevented by inhibition of NF-κB, and by alagebrium. 
Silencing of mRNA for RAGE prevented the increase in NF-kB induced by methylglyoxal. 
Silencing of mRNA for angiotensinogen prevented the increase in NF-κB, angiotensin, AT1 and 
α1D receptors’ protein. Methylglyoxal activates NF-κB through RAGE and thereby increases 
renin angiotensin levels, a novel finding, and a probable mechanism of increase in blood 
pressure.  
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4.2 Introduction 
Type 2 diabetes and hypertension are major global health issues. Two-thirds of the people 
with diabetes have hypertension [blood pressure (BP): systolic ≥ 140 mmHg or diastolic ≥ 90 
mmHg] (Ferrannini et al., 2012). The mechanism of the pathogenesis of hypertension in diabetes 
is not well established. The renin-angiotensin aldosterone system (RAAS) plays a major role in 
maintaining fluid balance, vascular tone and BP (Crowley et al., 2012; Fournier et al., 2012). 
Angiotensin II (Ang II) also increases activity of the sympathetic nervous system (Crowley et al., 
2012). Increased activity of the RAAS is seen in type 2 diabetics with hypertension (Hsueh et al., 
2011). Increased activity of the RAAS has also been proposed to be one of the etiologic factors 
for type 2 diabetes mellitus (Goossens, 2012; Luther et al., 2011; Zhou et al., 2012).  
Glucose is one of the main precursors for the formation of methylglyoxal (MG), a 
reactive aldehyde (Cooper et al., 1970; Dhar et al., 2008). Normally, MG is rapidly degraded 
mainly by the glyoxalase enzymes with the help of reduced glutathione (GSH) (Cooper, 1984). 
In conditions of excess MG formation, such as hyperglycemia, the glyoxalase enzymes get 
overwhelmed and the excess MG reacts with other proteins and enzymes and disrupts their 
normal function (Vander Jagt et al., 2003). Plasma MG levels are elevated in people with 
diabetes (McLellan et al., 1994; Wang et al., 2007a). We have recently shown that 
administration of MG for 4 weeks as a continuous infusion by a subcutaneous minipump induces 
features of type 2 diabetes in Sprague-Dawley rats (Dhar et al., 2011). MG is a major precursor 
for the formation of advanced glycation endproducts (AGEs) (Ahmed et al., 1997; Vander Jagt et 
al., 2003). MG causes increased oxidative stress (Desai et al., 2008; Wu et al., 2002), which in 
turn is believed to cause the pathophysiological changes in diabetes, hypertension, and aging 
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(Ceriello, 2008; Ceriello et al., 2004; Harman, 1998). For example, MG activates nuclear factor 
kappa B p65 (NF-κB p65), and inactivates antioxidant enzymes like glutathione reductase and 
glutathione peroxidase, in rat vascular smooth muscle cells (VSMCs), and causes oxidative stress 
(Wu et al., 2002). On the other hand increased oxidative stress can deplete GSH and slow down 
degradation of MG, thereby increasing its levels and harmful effects (Desai et al., 2008; Vander 
Jagt et al., 2003). Specific and safe scavengers of MG will have great therapeutic value to 
prevent hyperglycemia and high carbohydrate diet-induced pathology resulting from excess MG 
formation. Elevated plasma levels of MG have been reported in spontaneously hypertensive rats 
and fructose-fed rats (Wang et al., 2005; Wang et al., 2008), but it is not yet known whether MG 
is the cause or effect of hypertension. We hypothesized that MG upregulates the RAAS and 
increases BP in rats, as the basis of the work reported here. 
 
4.3 Methods 
Animals 
Male Sprague-Dawley rats from Charles River Laboratories (Quebec, Canada) were used 
according to guidelines of the Canadian Council on Animal Care. All animal protocols were 
approved by the University of Saskatchewan’s Animal Research Ethics Board. 28 male 12 week 
old Sprague-Dawley rats with closely matching body weights were used. A miniosmotic pump 
(Alzet® 2ML4, Durect Corp., Cupertino, CA, USA) was surgically implanted subcutaneously on 
the back under sterile conditions (Dhar et al., 2011). This pump holds a fixed volume (2 mL) of 
drug and releases a continuous small amount of MG (40% solution, Sigma-Aldrich Canada Ltd., 
Oakville, ON, Canada) into the body at a rate of 1 mg/h or 24 mg/day or 672 mg over 28 days. 
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Hence each rat received a fixed dose (24 mg/day) and therefore it is not expressed as mg/kg. To 
control for this fixed dose the rats were from the same batch, of the same age and similar in 
weight. We have successfully used this minipump previously to deliver MG to rats for 28 days 
(Dhar et al., 2011). Pumps were implanted in all rats to deliver either MG or normal saline (0.9% 
NaCl). Anesthesia was provided by a continuously monitored inhalation of isoflurane (Forane) 
(2-4%) in oxygen, delivered through a precision vaporizer and circle absorption breathing system 
(Ohio, 30/70 Proportioner Anesthesia Machine, Madison, Wisconsin), with the rat placed on a 
heated pad to maintain a rectal temperature of 37°C. Buprenorphine injection (0.025 mg/kg s.c. 
twice a day) was used as a preanesthetic and post-surgical recovery analgesic for two days 
following implantation.  
The rats were divided into the following treatment groups (n = 7 each): 1. Control (0.9% 
saline by pump), 2. MG (24 mg/day by pump), 3. MG + alagebrium (ALA, a MG scavenger 
(Dhar et al., 2010a), 30 mg/kg/day in drinking water), 4.  ALA + 0.9% saline by pump. At the 
end of the study, the rats were anaesthetized with sodium pentobarbital (60 mg/kg body weight, 
i.p.). After 15 min stabilization the BP was measured by carotid- artery cannulation for 30 min 
(Desai et al., 2006; Laight et al., 2000). Blood was collected from the carotid artery and plasma 
was separated and stored at -80°C. Organs / tissues cleaned in ice-cold phosphate buffer saline 
were immediately frozen in liquid nitrogen and stored at -80°C until processing. 
 
Biochemical assays 
Assay kits for quantitative determination of  plasma renin (AnaSpec, Fremont, CA, 
USA), angiotensin (Cayman Chemicals, Ann Arbor, USA), aldosterone (Cayman Chemical Co., 
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AnnArbor, MI, USA) and catecholamines (Rocky Mountain Diagnostics, Inc., Colorado Springs, 
CO, USA) were used according to the manufacturer’s instructions. 
 
Cell culture 
Rat thoracic aortic smooth muscle cells (A-10 cells, CRL-1476, American Type Culture 
Collection, Manassas, VA, USA) were cultured as described previously (Dhar et al., 2008). The 
cells were seeded either in 100 mm dishes for MG measurement or 6 well plates for other assays, 
with an equal amount of cells (10
6
/mL) in each well, and cultured to confluence. Cells were 
starved in FBS-free DMEM medium for 24 h prior to exposure to different treatments alone or in 
combination: MG  (30 μM based on preliminary results), glucose (5, 25 mM, based on 
preliminary results), ALA (100 μM) and a specific NF-κB inhibitor, CAY10512 (0.1 μM) 
(Cayman Chemical Co., Ann Arbor, MI, USA). 
 
Methylglyoxal measurement 
MG was measured by a specific and sensitive high-performance liquid chromatography 
(HPLC) method (Dhar et al., 2009). MG was derivatized with o-phenylenediamine to form the 
quinoxaline, 2-methylquinoxaline, which is very specific for MG. The 2-methylquinoxaline and 
the internal standard 5-methylquinoxaline were quantified on a Hitachi D-7000 HPLC system 
(Hitachi, Ltd., Mississauga, ON, Canada) via a Symmetry C18 column (3.9 x 150 mm, and 4 µm 
particle diameter; Waters, Milford, MA, USA).  
 
Western blotting  
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Total proteins from cultured cells, aortic tissue and kidney were subjected to Western blot 
analysis as previously described (Dhar et al., 2011; Dhar et al., 2012). The following primary 
antibodies were used: Ang II AT1 receptor (AT1R), adrenergic α1D receptor (α1DR), renin, 
angiotensin, angiotensin converting enzyme (ACE) (all from Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA), receptor for advanced glycation endproducts (RAGE), nuclear factor κB 
(NF-κB) (Abcam, Cambridge, MA, USA), and anti-β-actin (diluted 1:1000) (Sigma-Aldrich 
Canada Ltd., Mississauga, ON, Canada). Horse radish peroxidase conjugated secondary 
antibodies (Life Science, Hercules, CA, USA) (diluted 1:3000) were used. The proteins were 
visualized with ECL chemiluminescence reagent (GE Healthcare Life Sciences, Pittsburgh, PA, 
USA) and captured on X-ray film (GE Healthcare Life Sciences, Pittsburgh, PA, USA) (Dhar et 
al., 2011). 
 
Real time quantitative PCR (RT-PCR)  
Total  RNA from the cultured cells, kidney and aorta was isolated using RNA isolation 
kit (Qiagen, Germantown, MD, USA) (Dhar et al., 2011). The pre-designed primers for 
angiotensin, AT1R, α1DR, renin, aldosterone receptor (MR) and RAGE were purchased from 
Qiagen (Germantown, MD, USA). The real-time PCR was performed in an iCycler
 
iQ apparatus 
(Life Science, Hercules, CA, USA) associated with the
 
ICYCLER OPTICAL SYSTEM software 
(version 3.1) using SYBR Green
 
PCR Master Mix (Bio-Rad Laboratories Ltd., Mississauga, ON, 
Canada) as previously described (Dhar et al., 2011). 
 
siRNA transfection for RAGE and angiotensinogen  
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In a six well cell culture plate, 2 x 10
5
 cells per well were grown in 2 mL antibiotic-free 
normal growth medium supplemented with FBS. The cells were incubated at 37° C in an 
incubator until 60-80% confluent. For each transfection, 2-8 μL of siRNA duplex (Solution A, 
0.25-1 μg or 20-80 pmols siRNA) was diluted with 100 μL siRNA transfection medium (Cat # 
sc-36868, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). For each transfection, 2-8 μL 
of siRNA transfection reagent (Solution B, Cat # sc-29528, Santa Cruz Biotechnology Inc.) was 
diluted with 100 μL siRNA transfection medium (Cat # sc-36868). siRNA duplex solution 
(Solution A) was directly added to the dilute transfection reagent (Solution B) and mixed by 
pipetting the solution up and down, and incubated for 15-45 min at room temperature. The cells 
were washed once with 2 mL of siRNA transfection medium (Cat # sc-36868). For each 
transfection, 0.8 mL siRNA transfection medium was added to the siRNA transfection reagent 
mixture (Solution A + Solution B), mixed gently and added to the washed cells. The cells were 
incubated for 5-7 h at 37° C, followed by addition of 1 mL of normal growth medium containing 
2 times the normal serum and antibiotics concentration, to the transfection mixture. The cells 
were incubated further for 18-24 h. The medium was aspired and replaced with fresh 1x normal 
growth medium and the cells were assayed 48-72 h later. 
 
Materials 
Glucose, methylglyoxal and other reagents were purchased from Sigma Aldrich Canada 
Ltd. (Mississauga, ON, Canada) or VWR International (Mississauga, ON, Canada). Alagebrium 
(previously known as ALT-711, N-phenacyl-4,5-dimethyl-1,3-thiazolium) was a generous gift 
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from Synvista Therapeutics Inc. (Montvale, NJ, USA) (formerly Alteon Corp.). Synvista ceased 
operations in 2009 (BioSpace, 2009). 
 
Statistical analysis 
Data obtained from separate experiments are expressed as mean ± SEM. Statistical 
analysis was performed using ANOVA with post hoc Bonferroni’s test. A P value of less than 
0.05 was considered to be statistically significant. 
 
4.4 Results 
Acute or chronic methylglyoxal treatment increases cellular, aortic and renal 
methylglyoxal levels 
Incubation of cultured VSMCs for 24 h or 5 days with MG (30 µM) or high glucose (25 
mM) caused a significant elevation of cellular MG that was attenuated by co-incubation with the 
MG scavenger ALA (Fig. 4-1A, B). Treatment of SD rats for 4 weeks with MG caused a 
significant increase in aortic and renal MG levels which was attenuated by co-treatment with 
ALA (Fig. 4-1C, D).  
 
Chronic methylglyoxal treatment increases blood pressure and plasma catecholamines, 
renin, angiotensin and aldosterone levels 
Treatment of SD rats for 4 weeks with MG caused a significant increase in the BP which 
was attenuated by the MG scavenger ALA (Fig. 4-2A). ALA alone did not affect the BP. 
Chronic MG treatment also caused a significant increase in plasma norepinephrine, epinephrine, 
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dopamine (Fig. 4-2B), angiotensin (Fig. 4-2C), renin (Fig. 4-2D) and aldosterone (Fig. 4-2E) 
levels. The MG scavenger, ALA, attenuated the increase in catecholamines, angiotensin, renin 
and aldosterone caused by MG (Fig. 4-2). 
 
MG increases alpha1D receptor, AT1 receptor and angiotensin expression in vascular 
smooth muscle cells and the aorta. 
Glucose is a major precursor of MG formation (Dhar et al., 2008). Incubation of VSMCs 
with MG (30 µM) or high glucose (25 mM) for 24 h (Fig. 4-3Ai, ii, B) or 5 days (supplemental 
Fig. 4-S1) caused a significant increase in adrenergic α1D receptor, angiotensin AT1 receptor and 
angiotensin protein and mRNA, which were attenuated by ALA (Figs. 4-3Ai, ii, B, supplemental 
Fig. 4-S1).  
Chronic treatment of SD rats with MG for 4 weeks significantly elevated aortic 
adrenergic α1D receptor, angiotensin AT1 receptor and angiotensin protein and mRNA, which 
were attenuated by co-treatment with ALA + MG (Fig. 4-3Aiii, C).  
 
Chronic treatment of Sprague-Dawley rats with methylglyoxal increases renal AT1 
receptor, renin and angiotensin expression 
Chronic treatment of Sprague-Dawley rats with MG for 4 weeks significantly increased 
renal AT1 receptor, renin and angiotensin protein and mRNA, which were attenuated by co-
treatment with ALA (Fig. 4-4A, B).  
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Acute or chronic treatment with MG increases phosphorylated extracellular signal related 
kinases 1/2 (p-Erk 1/2) and NFATc expression 
Incubation of VSMCs with MG (30 µM) for 24 h (Fig. 4-5A) caused an increase in 
phosphorylated Erk 1/2 (p-Erk 1/2) and NFATc protein expression which was attenuated by 
ALA (Fig. 4-5A). Chronic treatment of Sprague-Dawley rats with MG for 4 weeks increased 
aortic and renal protein expression of p-Erk 1/2 and NFATc, which was attenuated by ALA 
(Figs. 4-5B, C).  
 
Effects of inhibition of NF-κB or angiotensinogen siRNA and receptor for AGEs (RAGE) 
siRNA on MG induced increase in NF-κB, angiotensin, AT1 and α1D receptors in VSMCs 
Incubation of VSMCs with MG (30 µM) for 24 h caused a significant increase in the 
protein and mRNA for NF-κB, angiotensin, AT1 and adrenergic α1D receptors, which were 
attenuated by co-incubation with the NF-κB inhibitor CAY 10512 (0.1 µM) or the MG 
scavenger, ALA (100 µM) (Fig. 4-6A-D). RAGE siRNA attenuated the increase in RAGE and 
NF-kB p65 protein expression induced by MG (30 µM) in cultured VSMCs (Fig. 4-6E). 
Angiotensinogen siRNA attenuated the increase in NF-kB p65, angiotensin, AT1 and adrenergic 
α1D receptor protein expression induced by MG (30 µM) in cultured VSMCs (Fig. 4-6F).  
 
4.5 Discussion 
We report the novel finding that MG, a reactive metabolite produced from glucose and 
fructose, significantly increases renin angiotensin aldosterone levels associated with an increase 
in the BP in Sprague-Dawley rats. Molecular studies in cultured VSMCs implicate RAGE and 
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NF-κB in the signaling pathway of MG to cause these effects. Alagebrium attenuates the 
pathological effects of MG on the RAAS.  
The association of hypertension, and increased cardiovascular fatalities such as 
myocardial infarction and stroke, with diabetes is well established (Ferrannini et al., 2012; Gee 
et al., 2012). High glucose (Kaufman et al., 1991) and high fructose diets (Hwang et al., 1987; 
Madero et al., 2011) have been shown to significantly increase the BP in animals and humans 
but the molecular mechanisms are not very clear. In the case of high glucose diet activation of 
protein kinase C, increased oxidative stress and reduced bioavailability of NO have been 
reported (Brownlee, 2001). In the case of high fructose diet one proposed mechanism implicates 
unregulated metabolism of fructose causing ATP depletion and an increase in uric acid, oxidative 
stress and decrease in NO production (Perez-Pozo et al., 2010; Sanchez-Lozada et al., 2007). 
Glucose and fructose are both precursors of MG formation (Dhar et al., 2008) and MG in turn is 
a well-established trigger for increased oxidative stress through multiple pathways (Desai et al., 
2008). MG is also a major precursor of the formation of AGEs (Ahmed et al., 1997; Vander Jagt 
et al., 2003).  
To the best of our knowledge our study is the first one to report a direct effect of MG on 
the development of hypertension and the probable molecular mechanisms. One study had 
reported administration of MG in drinking water for 18 weeks, and an increase in BP (Vasdev et 
al., 1998; Vasdev et al., 2010) but a direct link between MG and increased BP was not 
established. For example, plasma or aortic or renal MG levels were not measured. Instead renal 
levels of aldehyde conjugates (AGEs) were measured which likely represent modification of 
several proteins/enzymes, and do not identify individual proteins/enzymes and molecular 
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mechanisms. Moreover, in their study (Vasdev et al., 1998; Vasdev et al., 2010) the authors did 
not address the role of the RAAS. Moreover, MG reacts with epithelial cells of the intestines and 
the colon (Baskaran et al., 1990) and its oral bioavailability is questionable. An association of 
elevated MG with hypertension in rats has been shown but the cause effect relation was not 
established (Wang et al., 2007b; Wang et al., 2008).  
Increased activity of the RAAS is seen in type 2 diabetics with hypertension (Hsueh et 
al., 2011). Hyperglycemia and diabetes are known to increase renin angiotensin activity but the 
mechanism has not been clearly defined. In one study high levels of glucose were shown to 
cause the release of renin through local accumulation of succinate and activation of the kidney-
specific G protein-coupled receptor, GPR91, in the glomerular endothelium in rat, mouse, and 
rabbit (Toma et al., 2008). In another study 25 mM D-glucose increased the expression of 
angiotensinogen gene in cultured immortalized rat proximal tubular cells through synthesis of 
diacylglycerol and activation of protein kinase C (Toma et al., 2008; Zhang et al., 1999). We 
decided to examine the effect of MG on the RAAS. 
The oral absorption of MG is doubtful as determined in our preliminary studies, which 
failed to cause any significant increase in plasma MG levels. Therefore, we administered MG by 
continuous infusion of very small amounts with a minipump (Dhar et al., 2011), hoping to 
simulate the almost continuous production of MG in the body through metabolism. 
Administration of the dose of MG used in this study by minipump results in significant elevation 
of plasma MG levels to values reported in pathological conditions (Wang et al., 2005; Wang et 
al., 2008) and in our previous study (Dhar et al., 2011). This mode of MG administration 
significantly elevated MG levels in the kidney and the aorta (Fig. 4-1), which implicates MG in 
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the pathological effects on the RAAS. MG treatment increased plasma levels of renin, 
angiotensin, aldosterone and catecholamines (Fig. 4-2) signifying increased RAAS and 
adrenergic activity, which most likely increased the blood pressure. The kidney is the main 
source of renin and the major regulator of BP. The kidney had increased protein expression of 
renin, which would explain increased plasma renin. The renin in turn would produce more 
angiotensin II and its multiple effects (Fyhrquist et al., 2008; Hitomi et al., 2007; Zaman et al., 
2002).   
The aorta had significantly elevated MG. Previously we have shown that the aorta has 
significantly elevated levels of MG compared to other organs and tissues in normal SD rats, the 
reason being unknown, and it increases further after an acute infusion of MG (Dhar et al., 
2010a). The increased MG most likely increased aortic AT1 receptor, α1D receptor and 
angiotensin, because these effects were attenuated by the MG scavenger ALA. Both AT1 and α1D 
receptor activation can increase p-Erk 1/2 and NFATc, as seen here, which can contribute to 
increased vascular tone, inflammation and hypertension development (Hitomi et al., 2007). 
Increased AT1 and α1D receptors can increase vascular tone and BP (Fyhrquist et al., 2008; 
Zaman et al., 2002). We have previously shown (Dhar et al., 2010b) that MG can reduce 
endothelial nitric oxide synthase activity which can contribute to increased BP, although it was 
not investigated in this study.  
Treatment of VSMCs with MG or high glucose caused a similar significant increase in 
cellular MG levels, along with increased expression of AT1 receptor, α1D receptor and 
angiotensin, which were all attenuated by ALA (Fig. 4-1), which is a MG scavenger and an 
AGEs breaker (Dhar et al., 2010a; Wolffenbuttel et al., 1998). Since the attenuation by ALA of 
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increased MG levels, AT1 receptor, α1D receptor and angiotensin occurred within 24 h in cultured 
VSMCs (Fig. 4-3), this indicates a direct effect of MG on AT1 receptor, α1D receptor and 
angiotensin, rather than an indirect effect through MG-induced AGEs, which normally take 5-7 
days to form. High glucose similarly increased AT1 receptor, α1D receptor and angiotensin 
expression in VSMCs, which was attenuated by a MG scavenger, implicating MG as a mediator 
of the deleterious effects of hyperglycemia (Fig. 4-3). Since MG is a major precursor of AGEs 
formation, part of alagebrium’s preventive effects against MG could be due to prevention of 
AGEs formation in vivo, but not in 24 h cell culture studies. 
We investigated whether the effect of MG on angiotensin, AT1 and α1D receptors was 
direct, or indirect through some other mediators. RAGE is currently under intense investigation 
as a target to prevent diabetic complications (Ramasamy et al., 2011). The activation of RAGE 
by AGEs has been reported to increase two key transcription factors, NF-κB and early growth 
response-1 (Egr-1), and cause oxidative stress (Ramasamy et al., 2011; Wendt et al., 2002). We 
report the novel finding that MG can activate RAGE and up regulate it (Fig. 4-6E). RAGE is a 
receptor which is up regulated by its other known ligands (Ramasamy et al., 2011). Thus, when 
we silenced RAGE we were able to prevent the increase in NF-κB induced by MG (Fig. 4-6E). 
When we inhibited NF-κB we were able to prevent the increase in angiotensin, AT1 and α1D 
receptors in VSMCs (Fig. 4-6B-D), indicating an indirect effect of MG on these parameters. 
When we silenced angiotensin mRNA we were able to prevent the increase in angiotensin, AT1 
and α1D receptors and also the increase in NF-κB induced by MG (Fig. 4-6F). These results 
indicate that MG activates RAGE which then increases NF-κB followed by angiotensin, AT1 and 
α1D receptors. The increased angiotensin II in turn increases NF-κB and sets up a vicious cycle. 
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Our results establish a probable sequence of molecular events resulting from elevated MG levels 
which have been reported in high carbohydrate diet fed animals and in diabetic patients (Wang et 
al., 2007a; Wang et al., 2008).             
 
4.6 Conclusions 
We have shown a direct effect of MG in the development of hypertension and identified 
the probable involvement of the RAAS and RAGE in molecular mechanisms. Since diabetic 
patients are known to have significantly elevated MG levels (Wang et al., 2007a) and many 
people with diabetes develop hypertension, MG could possibly be a mediator of hyperglycemia-
induced and diabetes associated hypertension. High carbohydrate diets are known to induce 
hypertension in animal models and since glucose and fructose are both precursors for MG 
formation, MG could very likely be causing high dietary carbohydrate-induced hypertension, 
which is currently being investigated by us. The involvement of MG as one of the causative 
factors of hypertension and activator of RAGE opens up the possibility of using effective and 
safe MG scavengers in preventing diabetes associated hypertension and vascular complications. 
While the dietary habits of millions of people worldwide and the use of high fructose containing 
processed foods is not likely to change overnight, preventive strategies will play a major role in 
attenuating the adverse health effects of high carbohydrate diets. 
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Figure 4-1.  Methylglyoxal levels in cultured vascular smooth muscle cells and in the aorta 
and kidney of chronic methylglyoxal treated Sprague-Dawley rats. Vascular smooth muscle 
cells (A10 cell line) were incubated with MG (30 µM) or high glucose (Glu, 25 mM) for 24 h 
(A) or 5 days (B). Alagebrium (30 µM) was used as a MG scavenger. Groups (n = 7 each) of 12 
week old male Sprague-Dawley rats were treated for 4 weeks with a continuous infusion of 
methylglyoxal (MG, 24 mg/day) delivered by a subcutaneous minipump (C, D). Control rats 
received 0.9% saline by pump. Alagebrium (ALA, 100 mg/kg/day in drinking water) was used as 
a MG scavenger. MG levels were determined with HPLC. *P<0.05, **P<0.01 vs. respective 
control (Con). 
†
P<0.05, 
††
P<0.01 vs. respective MG. 
‡
P< 0.05, 
‡‡
P<0.01 vs. respective Glu 
group. 
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Figure 4-2.  Mean arterial blood pressure, plasma catecholamines, angiotensin, renin, and 
aldosterone levels in chronic methylglyoxal treated Sprague-Dawley rats. Groups (n = 7 
each) of 12 week old male Sprague-Dawley rats were treated for 4 weeks with a continuous 
infusion of methylglyoxal (MG, 24 mg/day) delivered by a subcutaneous minipump. Control rats 
received 0.9% saline by pump. Alagebrium (ALA, 100 mg/kg/day in drinking water) was used as 
a MG scavenger. Blood was collected and plasma was separated for analysis of MG by HPLC 
and catecholamines, renin, angiotensin and aldosterone by assay kits. *P<0.05, **P<0.01, 
***P<0.001 vs. respective control. 
†
P<0.05, 
††
P<0.01, 
†††
P<0.001 vs. respective MG group. 
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Figure 4-3.  α1D receptor, AT1 receptor and angiotensin protein expression in cultured 
vascular smooth muscle cells and in the aorta and mRNA in VSMCs and aorta of chronic 
methylglyoxal treated Sprague-Dawley rats. Rat thoracic aorta smooth muscle cells (VSMCs, 
A10 cell line) were cultured and incubated with MG (30 µM) (Ai, B) or high glucose (Glu, 25 
mM) (Aii, B) for 24 h. Alagebrium (ALA, 30 µM) was used as a MG scavenger. Groups (n = 7 
each) of 12 week old male Sprague-Dawley rats were treated for 4 weeks with a continuous 
infusion of methylglyoxal (MG, 24 mg/day) delivered by a subcutaneous minipump (Aiii, C). 
Control rats received 0.9% saline by pump. ALA (100 mg/kg/day in drinking water) was used as 
a MG scavenger. Protein expression was determined by Western blotting using appropriate 
β-actin
Co
n
M
G
 
M
G
+A
LA
α1DR
AT1R 
Ang II
Co
n
G
lu
G
lu
+A
LA
A VSMCs
24h
Co
n
M
G
 
M
G
+A
LA
Aorta
(i) (ii) (iii)
C
on M
G
G
lu
M
G
+A
LA
G
lu
+A
LA
0
50
100
150
200
250 1D AT1 Ang II
* * *
*
**
B
  
 m
R
N
A
 in
 V
S
M
C
s
 (
%
 C
on
tr
ol
: 
-a
ct
in
)
†
† †
‡ ‡ ‡
C
on M
G
M
G
+A
LA
0
50
100
150
200
250
300
350 1D AT1 Ang II
**
††
*
**
††
C
  
 m
R
N
A
 in
 a
or
ta
 (
%
 C
on
tr
ol
: 
-a
ct
in
)
†
  
 m
R
N
A
 in
 V
S
M
C
s
 (
%
 C
on
tr
ol
: 
-a
ct
in
)
  
 m
R
N
A
 in
 a
or
ta
 (
%
 C
on
tr
ol
: 
-a
ct
in
)
75 
 
primary antibodies, and mRNA with RT-PCR. *P<0.05, **P<0.01 vs. respective control (Con). 
†
P<0.05, 
††
P<0.01 vs. respective MG group. 
‡
P< 0.05 vs. respective Glu group.  
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Figure 4-4.  AT1 receptor, renin and angiotensin protein expression and mRNA in the 
kidney of chronic methylglyoxal treated Sprague-Dawley rats. Groups (n = 7 each) of 12 
week old male Sprague-Dawley rats were treated for 4 weeks with a continuous infusion of 
methylglyoxal (MG, 24 mg/day) delivered by a subcutaneous minipump. Control rats received 
0.9% saline by pump. Alagebrium (ALA, 100 mg/kg/day in drinking water) was used as a MG 
scavenger. Protein expression was determined by Western blotting using appropriate primary 
antibodies, and mRNA with RT-PCR. *P<0.05, **P<0.01 vs. respective control (Con). 
†
P<0.05, 
††
P<0.01 vs. respective MG group.   
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Figure 4-5.  Phosphorylated extracellular signal-related kinases 1/2 (p-Erk 1/2), Erk 1/2 
and NFATc expression in cultured vascular smooth muscle cells, and in the aorta and 
kidney of chronic methylglyoxal treated Sprague-Dawley rats. Rat thoracic aorta smooth 
muscle cells (VSMCs, A10 cell line) were cultured and incubated with MG (30 µM) (A) for 24 
h. Alagebrium (ALA, 30 µM) was used as a MG scavenger. Groups (n = 7 each) of 12 week old 
male Sprague-Dawley rats were treated for 4 weeks with a continuous infusion of methylglyoxal 
(MG, 24 mg/day) delivered by a subcutaneous minipump (B, C). Control rats received 0.9% 
saline by pump. ALA (100 mg/kg/day in drinking water) was used as a MG scavenger. Protein 
expression was determined by Western blotting using appropriate primary antibodies, and 
mRNA with RT-PCR. 
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Figure 4-6.  Nuclear factor κB (NF-κB), angiotensin, AT1 receptor, α1D receptor and 
receptor for advanced glycation endproducts (RAGE) expression in cultured vascular 
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smooth muscle cells treated with a NF-κB inhibitor, or after RAGE siRNA or 
angiotensinogen siRNA treatment. Vascular smooth muscle cells (A10 cell line) were cultured 
and incubated with MG (30 µM) for 24 h. CAY 10512 (0.1 µM) was used a NF-κB inhibitor. 
Alagebrium (ALA, 30 µM) was used as a MG scavenger (A-D). RAGE siRNA (E) or 
angiotensinogen siRNA (F) was carried out as explained in methods. Protein expression was 
determined by Western blotting using appropriate primary antibodies, and mRNA with RT-PCR.  
n = 4 for each group.  ***P<0.001 vs. respective control. 
†††
P<0.001 vs. respective MG group. 
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 Figure 4-S1.  α1D receptor, AT1 receptor and angiotensin expression in cultured vascular 
smooth muscle cells treated with methylglyoxal or high glucose. Rat thoracic aorta smooth 
muscle cells (A10 cell line) were cultured and incubated with MG (30 µM) (A, C) or high 
glucose (Glu, 25 mM) (B, D) for 5 days. Alagebrium (ALA, 30 µM) was used as a MG 
scavenger. Protein expression was determined by Western blotting using appropriate primary 
antibodies, and mRNA with RT-PCR. *P<0.05, **P<0.01 vs. respective control (Con).  
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5.1 Abstract 
The current epidemic of obesity and type 2 diabetes is attributed to a high carbohydrate 
diet, containing mainly high fructose corn syrup and sucrose.  More than two thirds of diabetic 
patients have hypertension. Methylglyoxal is a highly reactive dicarbonyl generated during 
glucose and fructose metabolism, and a major precursor of advanced glycation end products 
(AGEs). Plasma methylglyoxal levels are increased in hypertensive rats and diabetic patients. 
Our aim was to examine the levels of methylglyoxal, mediators of the renin angiotensin system 
and blood pressure in male Sprague-Dawley rats treated with a high fructose diet (60% of total 
calories) for 4 months.  The thoracic aorta and kidney were used for molecular studies, along 
with cultured vascular smooth muscle cells (VSMCs). HPLC, Western blotting and Q-PCR were 
used to measure methylglyoxal and reduced glutathione (GSH), proteins and mRNA, 
respectively. Fructose treated rats developed a significant increase in blood pressure.  
Methylglyoxal level and protein and mRNA for angiotensin II, AT1 receptor, adrenergic α1D 
receptor and renin were significantly increased, whereas GSH levels were decreased, in the aorta 
and/or kidney of fructose fed rats.  The protein expression of the receptor for AGEs (RAGE) and 
NF-κB were also significantly increased in the aorta of fructose fed rats.  MG treated VSMCs 
showed increased protein for angiotensin II, AT1 receptor, and α1D receptor. The effects of 
methylglyoxal were attenuated by metformin, a methylglyoxal scavenger and AGEs inhibitor. In 
conclusion, we report a strong association between elevated levels of methylglyoxal, RAGE, NF-
κB, mediators of the renin angiotensin system and blood pressure in high fructose diet fed rats.  
Key words: Methylglyoxal, hypertension, renin angiotensin system, diabetes, fructose, receptor 
for advanced glycation endproducts. 
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5.2 Introduction 
High dietary carbohydrates, increasing type 2 diabetes and obesity, and the associated 
hypertension and cardiovascular diseases are major health issues globally (Johnson et al., 2007; 
Selvaraju et al., 2012; Stanhope, 2012). The explosive increase in type 2 diabetes in the past 2-3 
decades has been attributed to high dietary carbohydrates, especially fructose, combined with a 
sedentary lifestyle. Compared to the general population the risk of high blood pressure (BP, 
systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg) is four times higher for people with 
diabetes (Diabetes, 2000). The pathogenesis of diabetes-associated hypertension is not clearly 
known. While it is believed to be initiated by hyperglycemia, the molecular mechanisms are far 
from clear.  
The Western diet has high fructose content, mainly in the form of high fructose corn 
syrup, which has been proposed to induce hypertension (Johnson et al., 2007; Stanhope, 2012). 
High fructose diet-fed Sprague-Dawley rats have been widely used as a model of insulin 
resistance and these rats also develop hypertension (Hwang et al., 1987; Wang et al., 2008). 
We have shown that fructose-fed Sprague-Dawley rats have elevated levels of 
methylglyoxal (MG), a reactive metabolite of glucose and fructose (Wang et al., 2008; Dhar et 
al., 2008). Elevated plasma levels of MG have been reported in spontaneously hypertensive rats 
which correlate with the degree of hypertension (Wang et al., 2005; Wang et al., 2007), but the 
cause-effect relationship and the underlying molecular mechanisms are not known. People with 
diabetes have significantly elevated levels of MG (Wang et al., 2007; McLellan et al., 1994). We 
have recently reported that chronic MG induces features of type 2 diabetes in SD rats (Dhar et 
al., 2011). MG is a major precursor for the formation of advanced glycation end products 
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(AGEs) (Desai & Wu, 2007; Vander & Husankar, 2003). MG reduces activity of antioxidant 
enzymes like glutathione reductase and glutathione peroxidase (Wu & Juurlink, 2002); leading to 
increased oxidative stress, which in turn is believed to cause the pathophysiological changes in 
diabetes, hypertension, and aging (Ceriello & Motz, 2004; Harman D, 1998). The pathogenesis 
of hypertension is multifactorial. Some of the factors include an increase in renin angiotensin 
aldosterone system (RAAS) activity, insulin resistance, renal disease and oxidative stress 
(Ceriello A, 2008; Cowley & Roman, 1996; Hall et al., 1990; Manrique et al., 2009). The RAAS 
plays an important role in maintaining fluid balance, vascular tone and blood pressure (Fyhrquist 
& Saijonmaa 2008; Zaman et al., 2002).  MG and angiotensin II (Ang II) both lead to an increase 
in oxidative stress (Manrique et al., 2009; Hitomi et al., 2007; Desai & Wu, 2008). Ang II 
stimulates NADPH oxidase by acting through the AT1 receptor and increases superoxide, 
hydrogen peroxide, and peroxynitrite (Hitomi et al., 2007). However, the cause and effect 
relationship between increased oxidative stress, RAAS activity and increased blood pressure has 
remained unclear.  
Therefore, the aim of this study was to examine and correlate the levels of MG, mediators 
of the renin angiotensin system and blood pressure in high fructose diet fed Sprague-Dawley 
rats.   
 
5.3 Materials and methods 
Animals 
Male Sprague-Dawley rats from Charles River Laboratories (Quebec, Canada) were used 
according to guidelines of the Canadian Council on Animal Care. All animal protocols were 
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approved by the University of Saskatchewan’s Animal Research Ethics Board. 32 male 5 week 
old Sprague-Dawley rats were randomly divided into the following treatment groups (n = 8 in 
each group): 1. Control (normal rat chow), 2. High fructose diet (60% of total calories), 3. High 
fructose diet + metformin (500 mg/kg/day in drinking water, MG scavenger (Beisswenger et al., 
1999; Ruggiero-Lopez et al., 1999), 4. Metformin (normal chow). The treatments were for 16 
weeks.  
At the end of the treatment period, the rats were anaesthetized with sodium pentobarbital 
(60 mg/kg body weight, i.p.). The trachea was cannulated to allow spontaneous respiration. The 
carotid artery was cannulated and connected to a pressure transducer and a Powerlab system (AD 
Instruments Inc., Colorado Springs, CO, USA) using LabChart 7 software. After 15 min 
stabilization the blood pressure was recorded for 30 min (Desai et al., 2006).  Blood was 
collected from the carotid artery and plasma was separated and stored at -80°C. The anesthetized 
rat was euthanized by cutting the thorax and the heart, and causing exsanguination, as per the 
guidelines of the Canadian Council on Animal Care. Organs and tissues cleaned in ice-cold 
phosphate buffer saline were immediately frozen in liquid nitrogen and stored at -80°C until 
processing. 
 
Cell culture 
Rat thoracic aortic smooth muscle cells (A-10 cells, CRL-1476, American Type Culture 
Collection, Manassas, VA, USA) were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin at 37° C in a 
humidified atmosphere of 95% air and 5% CO2, as described in our previous study (Dhar et al., 
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2008). The cells were seeded in 100 mm dishes, with an equal amount of cells (10
6
/mL) in each 
dish, and cultured to confluence. Cells were starved in FBS-free DMEM medium for 24 h prior 
to exposure to different treatments alone or in combination: MG  (30 μM based on preliminary 
results), and metformin (100 µM). 
 
Methylglyoxal measurement 
MG was measured by a specific and sensitive high-performance liquid chromatography 
(HPLC) method as described earlier (Dhar et al., 2009). MG was derivatized with o-
phenylenediamine to form the quinoxaline product, 2-methylquinoxaline, which is very specific 
for MG. The 2-methylquinoxaline and the internal standard 5-methylquinoxaline were quantified 
on a Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada) via a Symmetry 
C18 column (3.9 x 150 mm, and 4 µm particle diameter; Waters Corp., Milford, MA, USA).  
 
Western blotting  
Total proteins from cultured cells, aorta and kidney, were isolated with RIPA (lysis) 
buffer using a polytron homogenizer. The supernatants (40 μg of protein each) were separated by 
using 6-10% SDS-PAGE gel and subjected to Western blot analysis as previously described 
(Dhar et al., 2011) with overnight incubation with primary antibodies to AT1 receptor for 
angiotensin (AT1R), adrenergic α1D receptor (α1DR), renin, Ang II, (all from Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA), receptor for AGEs (RAGE), nuclear factor κB (NF-
κB) (Abcam, Cambridge, MA, USA), and anti-β-actin (diluted 1:1000) (Sigma-Aldrich Canada 
Ltd., Mississauga, ON, Canada). This was followed by incubation with horse radish peroxidase 
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conjugated secondary antibodies (Life Science, Hercules, CA, USA) (diluted 1:3000) for 2 h at 
room temperature. The proteins were then visualized with ECL chemiluminescence reagent (GE 
Healthcare Life Sciences, Pittsburgh, PA, USA) and exposed to X-ray film (GE Healthcare Life 
Sciences, Pittsburgh, PA, USA). 
 
Real time quantitative PCR (RT-PCR) 
Total RNA from the kidney and the aorta was isolated using RNA isolation kit (Qiagen, 
Germantown, MD, USA). The pre-designed primers for Ang II, AT1R, α1DR, renin and RAGE 
were purchased from Qiagen, (Germantown, MD, USA). The real-time PCR was performed in 
an iCycler
 
iQ apparatus (Life Science, Hercules, CA, USA) associated with the
 
ICYCLER 
OPTICAL SYSTEM software (version 3.1) using SYBR Green
 
PCR Master Mix (Bio-Rad 
Laboratories Ltd., Mississauga, ON, Canada). 
 
Measurement of reduced glutathione (GSH) 
Reduced glutathione was measured by derivatization with 5,5′-dithio-bis(2-nitrobenzoic 
acid), and reverse-phase HPLC using ultraviolet detection (Wang et al., 2008). 
 
Statistical Analysis 
Data obtained from separate experiments are expressed as mean ± SEM. Statistical 
analysis was performed using ANOVA with post hoc Bonferroni’s test. A P value of less than 
0.05 was considered to be statistically significant. 
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5.4 Results 
Chronic fructose treatment increases blood pressure, aortic and renal methylglyoxal levels 
Treatment of Sprague-Dawley rats with a high fructose diet for 16 weeks caused a 
significant increase in the blood pressure, which was attenuated by the MG scavenger metformin 
(Fig. 5-1A). Metformin alone did not affect the blood pressure. The high fructose diet also 
caused a significant elevation of aortic and renal MG levels, which was attenuated by co-
treatment with metformin (Fig. 5-1B, C). 
 
Chronic treatment with fructose increases aortic α1D receptor, AT1 receptor and angiotensin 
II expression 
Chronic treatment of Sprague-Dawley rats with fructose for 16 weeks significantly 
elevated aortic adrenergic α1D receptor, angiotensin AT1 receptor and Ang II protein and mRNA, 
which were attenuated by co-treatment with metformin (Fig. 5-2). Metformin alone was without 
any effect. 
 
Chronic treatment of Sprague-Dawley rats with fructose increases renal AT1 receptor, renin 
and angiotensin II expression 
Chronic treatment of Sprague-Dawley rats with fructose for 16 weeks significantly 
increased renal AT1 receptor, renin and Ang II protein and mRNA, which were attenuated by co-
treatment with metformin (Fig. 5-3). Metformin alone was without any effect. 
 
Chronic treatment with fructose increases phosphorylated extracellular signal related 
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kinases 1/2 (p-Erk 1/2), and NFATc expression 
Chronic treatment of Sprague-Dawley rats with fructose for 16 weeks increased aortic 
and renal protein expression of phosphorylated Erk 1/2  (p-Erk 1/2 ) and NFATc in the aorta, 
which was attenuated by metformin (Fig. 5-4A, B).  
 
Chronic treatment with fructose increases NF-κB and RAGE protein expression 
Chronic treatment of SD rats with fructose for 16 weeks significantly increased aortic and 
renal NF-κB and RAGE protein expression, which was attenuated by co-treatment with 
metformin (Fig. 5-5A, B).  
 
Chronic treatment with fructose decreases levels of reduced glutathione in the aorta and 
kidney  
Chronic treatment of Sprague-Dawley rats with fructose for 16 weeks significantly 
decreased aortic and renal levels of reduced glutathione, which were attenuated by co-treatment 
with metformin (Fig. 5-6A, B).  
 
Methylglyoxal increases α1D receptor, AT1 receptor and angiotensin II expression in 
cultured vascular smooth muscle cells 
Treatment of rat thoracic aortic cultured vascular smooth muscle cells with MG (30 µM) 
for 24 h significantly elevated adrenergic α1D receptor, angiotensin AT1 receptor and Ang II 
protein, which were attenuated by co-treatment with metformin (Fig. 5-7). Metformin alone was 
without any effect. 
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Metformin has MG scavenging ability 
As shown in table 1, 100 µM metformin significantly reduced the detectable free MG in 
solution after 3 h incubation, and about 30% of MG was detectable after 24 h incubation. A 
higher concentration of metformin (1 mM) was more effective in scavenging MG and it 
significantly reduced detectable free MG after 1 h of incubation and only about 10% of MG was 
detectable after 24 h.  
 
5.5 Discussion 
Here we show that 12 week old male Sprague-Dawley rats treated for 16 weeks with a 
high fructose diet, a precursor of MG, develop a significant increase in blood pressure. The 
kidney and aorta from fructose treated rats had significantly increased MG levels, and protein 
and mRNA for renin, Ang II, AT1 and adrenergic α1D receptors, which were attenuated by the 
MG scavenger metformin. MG treated cultured vascular smooth muscle cells had increased 
expression of Ang II, AT1 and α1D receptors, which was attenuated by metformin. 
Although high glucose (Kaufman et al., 1991) and high fructose diets (Hwang et al., 
1987; Madero et al., 2011) have been shown to significantly increase the blood pressure in 
animals and humans, the molecular mechanisms are not very clear. A high glucose diet-induced 
increase in blood pressure has been attributed to activation of protein kinase C, increased 
oxidative stress and reduced bioavailability of nitric oxide (Brownlee M, 2001). Fructose is 
metabolized differently than glucose with up to 75% of orally absorbed fructose being 
metabolized by the liver (Johnson et al., 2009). Moreover, the key enzyme of fructose 
metabolism, fructokinase is not feedback regulated by fructose metabolites (Johnson et al., 
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2009).  Thus, all of the orally absorbed fructose is phosphorylated by fructokinase (Johnson et 
al., 2009; Le et al., 2012). Unregulated metabolism of fructose causing ATP depletion, oxidative 
stress and decrease in nitric oxide production has been proposed as one of the mechanisms of 
fructose-induced increase in blood pressure (Perez-Pozo et al., 2010; Sanchez-Lozada et al., 
2007). Both glucose and fructose are precursors of MG formation (Dhar et al., 2008) and MG is 
also a well-established trigger for increased oxidative stress through multiple pathways (Desai & 
Wu, 2008). MG is also a major precursor of the formation of AGEs. (Desai & Wu, 2007; Vander 
& Husankar, 2003).    
The aorta and the kidney of fructose treated rats had significantly elevated MG levels 
(Fig. 5-1) which implicates MG as a factor in hypertension development. The kidney had 
increased protein expression of renin, which in turn would produce more Ang II and its multiple 
effects (Hitomi et al., 2007). The increased aortic MG, as observed in the present study, most 
likely increased aortic AT1 receptor, α1D receptor and Ang II. This effect of MG was confirmed 
by increased expression of AT1 receptor, α1D receptor and Ang II in MG treated cultured vascular 
smooth muscle cells (Fig. 5-7). Both AT1 and α1D receptor activation can increase p-Erk 1/2, and 
NFATc, as seen here, which can contribute to increased vascular contractility, inflammation and 
hypertension development (Hitomi et al., 2007; Michelotti et al., 2000). The increased Ang II 
may be responsible for the increased α1D receptor expression (Fyhrquist & Saijonmaa, 2008; 
Zaman et al., 2000). The increased Ang II, AT1 and α1D receptors in the aorta signify increased 
vascular tone. We were not able to harvest enough tissue from the mesenteric artery for western 
blot and PCR analysis. GSH levels were reduced in the aorta and the kidney of fructose treated 
rats (Fig. 5-6). GSH plays a central role in the degradation of MG by binding MG and making it 
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available to the glyoxalase enzymes (Vander & Husankar, 2003). A reduction in GSH would 
decrease MG degradation, increase its levels, and set up a vicious cycle.  
We addressed the possibility that MG was increasing oxidative stress, which has been 
implicated in the pathogenesis of hypertension (Ceriello A, 2008). The effect of MG on RAGE 
has not been reported before. RAGE is currently under intense investigation as a target to prevent 
diabetic complications. The activation of RAGE by AGEs has been reported to increase two key 
transcription factors, NF-κB and early growth response-1 (Egr-1), and cause oxidative stress 
(Ramasamy et al., 2011; Wendt et al., 2002). We observed increased RAGE and NF-κB in the 
aorta and the kidney of fructose treated rats. These results suggest that fructose treatment 
increases MG levels, which in turn can activate RAGE, which then increases NF-κB and 
oxidative stress. The increased oxidative stress increases expression of Ang II, AT1 and α1D 
receptors. The increased Ang II in turn can increase NF-κB and oxidative stress (Hitomi et al., 
2007) and set up a vicious cycle. Our results suggest a possible sequence of molecular events 
resulting from elevated endogenous MG levels which have been reported in high carbohydrate 
diet fed animals and in diabetic patients (Hwang et al., 1987; Wang et al., 2008; Wang et al., 
2007; McLellan et al., 1994). 
Metformin is used clinically as an oral anti-diabetic drug in patients with type 2 diabetes. 
Metformin has multiple effects in vivo. For example, it inhibits mitochondrial respiration and 
gluconeogenesis in the liver, activates AMP-activated protein kinase, increases insulin 
sensitivity, antagonizes the action of glucagon and increases fatty acid oxidation (Rena et al., 
2013). These in vivo antidiabetic actions of metformin can make interpretation of results 
difficult, making it a less than ideal experimental MG scavenger. Even though the MG 
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scavenging ability of metformin has been studied in specific experiments and reported before 
(Beisswenger et al., 1999; Ruggiero-Lopez et al., 1999), we tested the MG scavenging ability of 
metformin in cultured vascular smooth muscle cells treated with MG, where multiple in vivo, 
especially hepatic, actions of metformin do not come into play. We also performed an in vitro 
MG scavenging assay for metformin. In cultured vascular smooth muscle cells metformin 
attenuated the increased expression of α1D and AT1 receptors, and Ang II (Fig. 5-7). These results 
support a direct effect of MG on these RAAS mediators and the MG scavenging action of 
metformin. As shown in table 1 metformin displayed significant MG scavenging ability when the 
two were mixed in solution.  
 
5.6 Conclusions 
In conclusion, high fructose diet fed rats had significantly elevated blood pressure, MG 
levels in the aorta, and the kidney, and increased expression of Ang II, AT1 receptor, α1D 
receptor, renin, RAGE and NF-κB and decreased levels of reduced glutathione in the aorta 
and/or the kidney. The MG scavenger metformin attenuated these effects. Our results show a 
strong association between elevated levels of methylglyoxal, RAGE, NF-κB, mediators of the 
renin angiotensin system and blood pressure in high fructose diet fed rats. Therefore, it is 
possible that MG could be a mediator of high fructose diet-induced hypertension, probably 
acting through RAGE and NF-κB, and up regulating the renin angiotensin system.  
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Figure 5-1.  Mean arterial blood pressure and methylglyoxal (MG) levels in the aorta and 
kidney of high fructose diet treated Sprague-Dawley rats. Groups (n = 8 each) of 5 week old 
male Sprague-Dawley rats were treated for 16 weeks with a high fructose diet (Fruc, 60% of 
total calories). Control rats received normal chow. Metformin (Met, 500 mg/kg/day in drinking 
water) was used as a MG scavenger. Mean arterial pressure was measured with an intra-carotid 
artery catheter in anesthetized rats. MG levels were determined with HPLC. **P<0.01 vs. 
respective control (Con). 
†
P<0.05, 
††
P<0.01 vs. respective Fruc group. 
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Figure 5-2.  Adrenergic α1D receptor (α1DR), AT1 angiotensin receptor (AT1R) and 
angiotensin II (Ang II) expression and mRNA in the aorta of high fructose diet treated 
Sprague-Dawley rats. Groups (n = 8 each) of 5 week old male Sprague-Dawley rats were 
treated for 16 weeks with a high fructose diet (Fruc, 60% of total calories). Control rats received 
normal chow. Metformin (Met, 500 mg/kg/day in drinking water) was used as a MG scavenger. 
Protein expression was determined by Western blotting using appropriate primary antibodies, 
and mRNA with RT-PCR. *P<0.05, **P<0.01 vs. respective control (Con). 
†
P<0.05 vs. 
respective Fruc group. 
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Figure 5-3.  AT1 angiotensin receptor (AT1R), renin and angiotensin II (Ang II) expression 
and mRNA in the kidney of high fructose diet treated Sprague-Dawley rats. Groups (n = 8 
each) of 5 week old male Sprague-Dawley rats were treated for 16 weeks with a high fructose 
diet (Fruc, 60% of total calories). Control rats received normal chow. Metformin (Met, 500 
mg/kg/day in drinking water) was used as a MG scavenger. Protein expression was determined 
by Western blotting using appropriate primary antibodies, and mRNA with RT-PCR. *P<0.05 
vs. respective control (Con). 
†
P<0.05 vs. respective Fruc group.   
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Figure 5-4. Phosphorylated extracellular signal-related kinases 1/2 (p-Erk 1/2), Erk 1/2 and 
NFATc expression in the aorta and kidney of high fructose diet treated Sprague-Dawley 
rats. Groups (n = 8 each) of 5 week old male Sprague-Dawley rats were treated for 16 weeks 
with a high fructose diet (Fruc, 60% of total calories). Control rats received normal chow. 
etformin (Met, 500 mg/kg/day in drinking water) was used as a MG scavenger. Protein 
expression was determined by Western blotting using appropriate primary antibodies. 
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Figure 5-5.  Receptor for advanced glycation endproducts (RAGE) and nuclear factor κB 
(NF-κB) expression in the aorta and kidney of high fructose diet treated Sprague-Dawley 
rats. Groups (n = 8 each) of 5 week old male Sprague-Dawley rats were treated for 16 weeks 
with a high fructose diet (Fruc, 60% of total calories). Control rats received normal chow. 
Metformin (Met, 500 mg/kg/day in drinking water) was used as a MG scavenger. Protein 
expression was determined by Western blotting using appropriate primary antibodies.   
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Figure 5-6.  Reduced glutathione (GSH) levels in the aorta and kidney of high fructose diet 
treated Sprague-Dawley rats. Groups (n = 8 each) of 5 week old male Sprague-Dawley rats 
were treated for 16 weeks with a high fructose diet (Fruc, 60% of total calories). Control rats 
received normal chow. Metformin (Met, 500 mg/kg/day in drinking water) was used as a MG 
scavenger. Glutathione levels were determined with HPLC. *P<0.05, **P<0.01 vs. respective 
control. 
†
P<0.05, vs. respective Fruc group. 
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Figure 5-7.  α1D receptor (α1DR), AT1 receptor (AT1R) and Angiotensin II (Ang II) 
expression in cultured vascular smooth muscle cells (VSMCs) treated with methylglyoxal. 
Rat thoracic aorta smooth muscle cells (A10 cell line) were cultured and incubated with MG (30 
µM) for 24 h. Metformin (100 µM) was used as a MG scavenger. Protein expression was 
determined by Western blotting using appropriate primary antibodies.  n = 4 for each group.  
*P<0.05, **P<0.01 vs. respective control (Con). 
†
P<0.05, 
††
P<0.01 vs. respective MG group. 
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Incubation 
time 
MG (30 µM) MG (30 µM) + 
metformin (100 
µM) 
MG (30 µM) + 
metformin (1 mM) 
Metformin 
(100 µM) 
Metformin  
(1 mM) 
15 min 24.89 ± 0.15 21.69 ± 0.17 18.79 ± 0.21 0 0 
30 min 25.28 ± 0.21 19.29 ± 0.06 15.28 ± 0.32 0 0 
60 min 26.82 ± 0.15 17.87 ± 0.31 10.38 ± 0.51* 0 0 
3 h 25.77 ± 0.14 12.52 ± 0.08* 7.36 ± 0.27** 0 0 
24 h 25.23 ± 0.31 9.43 ± 0.41** 3.39 ± 0.32*** 0 0 
 
Table 5-1. In vitro assay to determine the methylglyoxal (MG) scavenging ability of 
metformin. MG was incubated with metformin at different concentrations at 37ºC for different 
times. The solution was analyzed for free MG by HPLC after the given incubation period. The 
values (µM) are expressed as mean ± SEM (n = 6 in each). 
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6.1 Abstract 
Aims. Methylglyoxal (MG), a reactive metabolite of glucose, has high affinity for arginine and is 
a major precursor of advanced glycation endproducts. Specific and safe MG scavengers are not 
available. We investigated whether L-arginine and D-arginine can attenuate endothelial 
dysfunction and oxidative stress induced by MG and high glucose, and implications for arginase 
for which L-arginine is a substrate. 
Methods and results. We used isolated aortic rings from 12 week old male Sprague-Dawley rats 
and cultured human umbilical vein endothelial cells (HUVECs) and vascular smooth muscle 
cells (VSMCs). L- and D-arginine both attenuated MG and high glucose induced reduced 
endothelium-dependent relaxation by acetylcholine, but only L-arginine attenuated inhibition of 
relaxation by the nitric oxide synthase inhibitor, Nω-nitro-L-arginine methyl ester. MG and high 
glucose increased protein expression of arginase, NADPH oxidase 4, nuclear factor kappa B, and 
reactive oxygen species production in HUVECs and VSMCs, which were attenuated by L- and 
D-arginine. However, L- and D-arginine did not attenuate the MG and high glucose-induced 
increased arginase activity in VSMCs. MG and high glucose-induced increased formation of the 
MG-specific advanced glycation endproduct, Nε-carboxyethyl lysine, in VSMCs was attenuated 
by L- and D-arginine. 
Conclusions. MG and high glucose increase arginase protein and activity which may contribute 
to endothelial dysfunction. L-arginine and D-arginine attenuate the endothelial dysfunction and 
increased oxidative stress induced by MG and high glucose by an endothelial nitric oxide 
synthase independent mechanism, despite increased arginase activity. The potential of arginine 
as a safe MG scavenger needs to be followed up. 
104 
 
6.2 Introduction 
L-arginine (L-Arg), but not D-arginine (D-Arg), is a substrate for nitric oxide synthase 
(NOS), which catalyzes the formation of nitric oxide (NO) and L-citrulline (Palmer et al., 1988). 
There are three isoforms of NOS, endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal 
NOS (nNOS) (Moncada et al., 1991). eNOS is mainly found in the endothelial cells and 
mediates endothelium-dependent agonist induced vessel relaxation (Moncada et al., 1991). 
Reduced production or availability of NO is a common feature of endothelial dysfunction (De 
Vriese et al., 2000; Potenza et al., 2009), which is commonly defined as reduced endothelium-
dependent vascular relaxation, and is a feature of diabetes, atherosclerosis, hypertension and 
several other conditions.   
L-Arg, but not D-Arg, is also a substrate for arginase, which is an enzyme of the urea 
cycle that catalyzes the formation of urea and ornithine. There are two isoforms, arginase I and 
arginase II (Haraguchi et al., 1987; Morris et al., 1997). In blood vessels, arginases are mainly 
expressed in the endothelium and at low levels in vascular smooth muscle cells (VSMCs) (Wei 
et al., 2000). Increased expression of VSMC arginase may contribute to intimal hyperplasia and 
vascular stiffness (Marinova et al., 2008; Wei et al., 2001). Endothelial arginase may be 
affecting eNOS function and can be responsible for endothelial dysfunction (Berkowitz et al., 
2003; Zhang et al., 2001). High glucose (25 mM) has been shown to increase arginase I activity, 
but not protein expression, in bovine coronary endothelial cells, and arginase I is increased in the 
aorta of streptozotocin diabetic rats (Romero et al., 2008), causing endothelial dysfunction 
(Ishizaka et al., 2007; Romero et al., 2008).  
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Methylglyoxal (MG) is produced during glucose, fatty acid and amino acid metabolism 
to varying degrees (Thornalley, 1996). MG is a reactive dicarbonyl molecule which can react 
with arginine (Shipanova et al., 1997; Takahashi, 1977), lysine and cysteine residues (Ahmed et 
al., 1997) of exposed functional groups of proteins and enzymes and cause their structural and 
functional disruption (Dhar et al., 2010b; Jia et al., 2006). MG is a major precursor for the 
formation of advanced glycation end products (AGEs) and is clearly of great pathological 
significance (Kilhovd et al., 2003). Under physiological conditions the MG produced in the body 
is efficiently degraded by the glyoxalase enzymes and reduced glutathione (GSH) into D-lactate 
(Thornalley, 1993; Vander Jagt et al., 2003) to maintain plasma MG levels at around 1 μM or 
less. MG formation increases in diabetes (Thornalley, 1988) and diabetic patients have 3-4 fold 
elevated plasma MG levels (McLellan et al., 1994; Wang et al., 2007).  
Incubation of vascular smooth muscle cells with 25 mM glucose or fructose for 3 h 
increases MG production 3.5 or 3.9 fold, respectively, and increases oxidative stress (Dhar et al., 
2008). We have recently shown that in cultured rat aortic and human umbilical vein endothelial 
cells MG and high glucose reduced basal and bradykinin-stimulated nitric oxide (NO) 
production, cyclic guanosine monophosphate levels, and serine-1177 phosphorylation and 
activity of endothelial nitric oxide synthase (eNOS) without affecting threonine-495 and Akt 
phosphorylation, and total eNOS protein (Dhar et al., 2010b). Chronic treatment of Sprague-
Dawley rats with MG for 4 weeks induces features characteristic of type 2 diabetes mellitus.  
Evidently, safe and specific MG scavengers have the potential to prevent several different 
pathological conditions such as endothelial dysfunction, type 2 diabetes and AGEs formation.  
Currently, there is a lack of safe and specific MG scavengers. Several investigators have used 
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different compounds as MG scavengers, which have other actions and thus are non-specific and 
can even produce toxicity. These compounds include aminoguanidine (Brownlee et al., 1986; 
Edelstein et al., 1992), alagebrium (Dhar et al., 2010a; Little et al., 2005; Wolffenbuttel et al., 
1998), N-acetyl cysteine (Jia et al., 2007; Vasdev et al., 1998) and metformin (Beisswenger et 
al., 2003; Ruggiero-Lopez et al., 1999; Wang et al., 2008). Since MG has been reported to have 
high affinity for arginine (Takahashi, 1977), our aim was to investigate and compare the effects 
of L-Arg and D-Arg on MG and high glucose-induced endothelial dysfunction and oxidative 
stress. We also examined the effects of MG on arginase expression and activity, which has not 
been reported previously.  
 
6.3 Methods and materials 
Animals 
Male 11-week old Sprague-Dawley rats from Charles River Laboratories (Quebec, 
Canada) were used according to a protocol approved by the Animal Care Committee at The 
University of Saskatchewan, following guidelines of the Canadian Council on Animal Care. The 
investigation conforms with the Guide for the Care and Use of Laboratory Animals published by 
the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). After one week 
of acclimatization, the rats were anesthetized with an inhalation of isoflurane (Forane, 4% in 
oxygen), delivered through a precision vaporizer and circle absorption breathing system (Ohio, 
30/70 Proportioner Anesthesia Machine, Madison, Wisconsin). When anesthesia reached 
sufficient depth as determined by the absence of the leg flexor response and the eyelid reflex, the 
thorax was quickly opened by a midline incision and the rat was killed by cutting the heart open 
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and causing exsanguination. The aorta was quickly removed without damaging the endothelium 
and placed in a beaker filled with Kreb’s solution and bubbled with 95% O2 + 5% CO2.  
 
Isometric tension studies on aortic rings 
A group of 24 Sprague-Dawely rats was used. Isometric tension studies were carried out 
on rat aortic rings as described (Dhar et al., 2010b). Briefly, 3-4 mm thoracic aortic rings from 
Sprague-Dawley rat were mounted under a 2 g load in four separate 10
 
mL organ baths 
containing Krebs solution with 5 mM glucose and maintained at 37° C and bubbled with 95% O2 
+ 5% CO2. After a 90 min equilibration period the rings were pre-contracted with phenylephrine 
(1 µM) and cumulative concentration-dependent relaxation in response to acetylcholine (ACh) 
was obtained before (Control) and 2 h after incubation with either glucose (25 mM) or MG (100 
μM) (Dhar et al., 2010b), or the nitric oxide synthase inhibitor, Nω-nitro-L-arginine methyl ester 
(L-NAME, 10 μM). In initial experiments the responses to ACh were repeated before and 2 h 
after incubation with normal Krebs solution to confirm reproducibility of responses to ACh. 
Some sets of rings were co-incubated with either L-Arg (300 μM) or D-Arg (300 µM) for 2 h. 
Treatment with each compound was tested in rings from at least 5 different rats. Isometric
 
tension was measured with isometric force transducers with the ‘Chart’ software and Powerlab 
equipment (AD Instruments Inc., Colorado Springs, CO, USA).  
 
Methlyglyoxal assay 
MG was measured by a specific and sensitive HPLC method as described previously 
(Dhar et al., 2009). MG was derivatized with o-phenylenediamine (o-PD) to specifically form 2-
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methylquinoxaline. The samples were incubated in the dark for 24 h with 0.45 N perchloric acid 
(PCA) and 10 mM o-PD at room temperature. Samples were centrifuged at 12000 rpm for 10 
min. 2-methylquinoxaline and quinoxaline internal standard (5-methylquinoxaline) were 
quantified on a Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada) via 
Nova-Pak® C18 column (3.9×150 mm, and 4 μm particle diameter, Waters Corporation, 
Milford, MA, USA). 
 
Cell culture 
Rat thoracic aortic smooth muscle cell line (A-10 cells) was obtained from American 
Type Culture Collection and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 10% fetal bovine serum (FBS) at 37° C in a humidified atmosphere of 95% air and 
5% CO2, as described in our previous studies (Dhar et al., 2008). A-10 cells were seeded either 
in 100 mm dishes for MG measurement or in 96-well plates for other assays, with an equal 
amount of cells (10
6
/mL) in each well, and cultured to confluence. For immunocytochemistry 
staining, cells were seeded on cover glass slides (2×10
6
/mL). Cells were starved in FBS-free 
DMEM for 24 h before exposure to different metabolic precursors.  
Human umbilical vein endothelial cells (HUVECs) from American Type Culture 
Collection were cultured in Kaighn’s F12K medium containing 10% fetal bovine serum (FBS), 
0.1 mg/mL heparin and 0.03-0.05 mg/mL endothelial cell growth supplement (Dhar et al., 
2010b).  
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Western blotting 
Cell lysates were prepared as described earlier (Dhar et al., 2010b; Dhar et al., 2011)  and 
the protein concentration in the supernatant was determined by the BCA Protein assay (Bio-Rad, 
Hercules, CA, USA). Aliquots of cell lysates (50 μg of protein each) were separated on 7.5-10% 
SDS-PAGE, electrotransferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad), 
blocked with 5% nonfat milk in TBS-Tween buffer for 2 h at room temperature, and incubated 
overnight at 4° C with the primary antibodies to arginase I, arginase II, nuclear factor kappa B 
(NF-κB) or NADPH oxidase 4 (NOX4) (Santa Cruz, CA, USA), and then with horseradish 
peroxidase conjugated secondary antibody (Santa Cruz, CA, USA) for 1 h at room temperature. 
After extensive washing, the immunoreactive proteins were detected with an Enhanced 
Chemiluminescence Detection System (ECL; Amersham Biosciences Corp., Piscataway, NJ, 
USA) (Dhar et al., 2010b; Dhar et al., 2011).  
 
Arginase activity assay 
Arginase activity was measured using an arginase assay kit (BioAssays Systems, CA, 
USA). Arginase catalyses the conversion of arginine to orinithine and urea. Briefly, cell lysates 
were mixed with substrate arginine buffer and incubated for 2 h. Urea reagent was added to stop 
the reaction and the optical density measured at 430 nm. 
 
Measurement of reactive oxygen species 
Confluent cells were loaded with a membrane-permeable, nonfluorescent probe 2’,7’-
dichlorofluorescin diacetate (CM-H2DCFDA, 5 μM) for 2 h at 37° C in FBS-free medium in the 
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dark. The cells treated with MG (30 μM) or glucose (25 mM) for 24 h were assayed for 
fluorescent oxidized dichlorofluorescein (DCF) as an indicator of production of reactive oxygen 
species (ROS) as described earlier (Dhar et al., 2008; Dhar et al., 2010b). The protein content of 
the homogenate was measured by BCA Protein assay (Bio-Rad, Hercules, CA, USA).  
 
Immunocytochemistry  
A-10 cells were seeded on glass cover slips followed by incubation with different test 
compounds for 24 h, and subjected to staining for the MG-induced AGE, Nε-carboxyethyl lysine 
(CEL). As described previously (Dhar et al., 2008; Dhar et al., 2011), the treated cells were fixed 
in 4% paraformaldehyde for 30 min at room temperature and washed twice with 0.01 N 
phosphate buffered saline (PBS). After permeation with 0.1% Triton X-100 for 5 min and two 
washes with PBS, the cells were incubated with normal goat serum (diluted 1:30 in 0.1 N PBS) 
for 1 h to block non-specific binding sites. After shaking off the goat serum the slides were 
incubated with the CEL antibody (1:100; a generous gift from Novo Nordisk, A/S, Denmark) 
overnight at room temperature. Cells were washed twice in PBS (0.01 N) for 5 min and 
incubated with secondary fluorescein isothiocynate (FITC) conjugated anti-CEL antibody 
(Molecular Probes) for 2 h. After washing thrice with PBS the slides were mounted in 
glycerol:PBS (3:7), coverslipped and observed under a fluorescence microscope. Staining 
intensity was quantified using the Metamorph image analysis software (v. 7, Molecular Devices). 
Slides from four different experiments were analyzed with 5 fields per slide observed and 
averaged. 
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Chemicals and statistical analysis 
All chemicals were of analytical grade. Methylglyoxal, D-glucose, L-arginine and D-
arginine were purchased from Sigma Aldrich, Oakville, ON, Canada. Cell culture media and 
reagents were purchased from Invitrogen Canada Inc., Burlington, ON, Canada. Data are 
expressed as mean ± SEM and analyzed using one way ANOVA and post hoc Bonferroni’s test. 
The P value was considered significant when it was less than 0.05. 
 
6.4 Results 
L-arginine and D-arginine prevent methylglyoxal and high glucose induced reduction of 
acetylcholine-induced relaxation of aortic rings 
In rat aortic rings precontracted with phenylephrine (1 µM), MG (100 µM, Fig. 6-1A, B) 
as well as high glucose (25 mM, Fig. 6-1C, D) incubated for 2 h in the bath caused significant 
inhibition of ACh-induced endothelium-dependent relaxation, which was prevented by 
coincubation of L-Arg (300 µM, Fig. 6-1A, C) or D-Arg (300 µM, Fig. 6-1B, D) with MG (Fig. 
6-1A, B) or high glucose (Fig. 6-1C, D). Incubation of the eNOS inhibitor, Nω-nitro-L-arginine 
methyl ester (L-NAME 10 µM, Fig. 6-1E, F) prevented ACh-induced relaxation, which was 
restored by co-incubation of L-Arg (300 µM, Fig. 6-1E), but not D-Arg (300 µM, Fig. 6-1F), 
with L-NAME.  
L-Arg and D-Arg (300 µM) did not affect ACh-induced relaxation of the rings (data not 
shown). MG and glucose did not affect endothelium-independent relaxation of aortic rings 
induced by sodium nitroprusside (data not shown).  
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L-arginine and D-arginine prevent high glucose-induced elevation of methylglyoxal levels 
in vascular smooth muscle cells 
Incubation of VSMCs with MG (30 µM) (Fig. 6-2A) or high glucose (25 mM) (Fig.6-
2B) for 24 h significantly increased the level of cellular MG to a similar extent, which was 
prevented by coincubation with L-Arg or D-Arg (300 µM) (Fig. 6-2). L-Arg or D-Arg alone did 
not affect basal MG levels in VSMCs (Fig. 6-2).  
 
Methylglyoxal and high glucose increase arginase I and II expression and activity
 Incubation of HUVECs (Fig. 6-3A, C) or VSMCs (Fig. 6-3B, D) with MG (30 µM) (Fig. 
6-3A, B) or high glucose (25 mM) (Fig. 6-3C, D) for 24 h significantly increased arginase I and 
II protein expression in both cell types, which was attenuated by co-incubation with L-Arg (300 
µM) or D-Arg (300 µM).  
Incubation of VSMCs with MG (30 µM) or high glucose (25 mM) for 24 h significantly 
increased total arginase activity (Fig. 6-3E). L-Arg (300 µM) or D-Arg (300 µM) co-incubated 
with MG or high glucose further increased arginase activity (Fig. 6-3E). However, L-Arg (300 
µM) or D-Arg (300 µM) alone did not increase arginase activity (Fig. 6-3E). 
 
L-arginine and D-arginine prevent methylglyoxal and high glucose-induced increased 
expression of nuclear factor κB and NADPH oxidase 4 
Incubation of cultured HUVECs (Fig. 6-4A, C) or VSMCs (Fig. 6-4B, D) with MG (30 
µM) (Fig. 6-4A, B) or with high glucose (25 mM) (Fig. 6-4C, D) for 24 h significantly increased 
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the protein expression of NF-κB and NOX4 in both cell types, which was attenuated by co-
incubation with L-Arg (300 µM) or D-Arg (300 µM) (Fig. 6-4).  
 
L-arginine and D-arginine prevent methylglyoxal and high glucose-induced oxidative 
stress  
Incubation of cultured HUVECs (Fig. 6-5) or VSMCs (Fig. 6-6) with MG (30 µM or 100 
µM) (Figs. 6-5A, B and 6-6A, B), or with high glucose (25 mM) (Figs. 6-5C and 6-6C)  for 3 h 
or 24 h significantly increased oxidative stress as measured by oxidized dichlorofluorescein. 
Both L-Arg (300 µM) and D-Arg (300 µM) co-incubated with MG or glucose attenuated the 
increase in oxidative stress (Figs. 6-5 and 6-6). L-Arg and D-Arg alone did not affect basal DCF 
levels (data not shown). 
 
L-arginine and D-arginine prevent methylglyoxal and high glucose-induced increased 
formation of Nε-carboxyethyl lysine (CEL)  
Incubation of cultured VSMCs with MG (30 µM) or with high glucose (25 mM) (Figs. 6-
5C and 6-6C) for 24 h significantly increased the formation of the MG-specific AGE, CEL 
(bright green stain) (Fig. 6-7). Co-incubation with L-Arg (300 µM) or D-Arg (300 µM) 
attenuated the formation of CEL (Fig 6-7).  
 
6.5 Discussion 
We aimed to investigate the potential of arginine as a MG scavenger by focusing on 
endothelial dysfunction induced by MG and high glucose. We have reported the molecular 
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mechanisms of eNOS dysfunction caused by MG and high glucose in a recent paper (Dhar et al., 
2010b), so we investigated whether L-Arg and D-Arg can attenuate MG and high glucose-
induced reduced ACh-induced relaxation in aortic rings. Additionally and importantly, we also 
considered effects on arginase since it has been recognized as a contributor to endothelial 
dysfunction (Berkowitz et al., 2003; Ishizaka et al., 2007) and also uses L-Arg as a substrate 
(Morris, 2009). We report the following novel findings: 1. MG up regulates arginase I and 
arginase II protein expression in cultured HUVECs and VSMCs, 2. MG increases arginase 
activity in VSMCs, 3. high glucose up regulates arginase I and II protein expression and activity 
in VSMCs, 4. L-Arg and D-Arg attenuate the effects of MG and high glucose in rat isolated 
aortic rings and cultured HUVECs and VSMCs for the parameters tested except for increased 
arginase activity, and the effect of L-Arg and D-Arg against MG and high glucose is most likely 
independent of eNOS.  
We examined endothelial dysfunction, which is a hallmark of prediabetes (Su et al., 
2008), type 1 and type 2 diabetes (De Vriese et al., 2000; Potenza et al., 2009) and precedes the 
development of cardiovascular complications of diabetes (De Vriese et al., 2000; Potenza et al., 
2009; Su et al., 2008). It has been widely ascribed to reduced NO availability (De Vriese et al., 
2000; Dhar et al., 2010b; Potenza et al., 2009). We have recently shown that MG and high 
glucose cause reduced serine 1177 phosphorylation and activity of eNOS, NO production and 
ACh-induced endothelium-dependent relaxation, which was prevented by the MG scavenger 
aminoguanidine (Dhar et al., 2010b).  
L-Arg as well as D-Arg attenuated the reduced ACh-induced endothelium dependent 
relaxation of the aortic rings, but only L-Arg prevented the inhibition of ACh-induced relaxation 
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by the NOS inhibitor, L-NAME (Fig. 6-1). L-Arg, but not D-Arg, is a substrate of NOS (Palmer 
et al., 1988) and since D-Arg also prevented MG and high glucose-induced reduced relaxation 
but not that caused by L-NAME, it strongly suggests that arginine prevents MG and high 
glucose-induced reduced relaxation by an eNOS independent mechanism.  
One of the deleterious effects of MG and high glucose is an increase in oxidative stress 
(Dhar et al., 2008; Dhar et al., 2010b; Wu et al., 2002), which can be attributed to increased 
activity of NADPH oxidase (Dhar et al., 2010b) and NF-κB (Wu et al., 2002). We have recently 
shown that MG and high glucose cause reduced ACh-induced relaxation of aortic rings partly by 
increasing NADPH oxidase activity and oxidative stress (Dhar et al., 2010b). In this study L-
Arg and D-Arg attenuated the increased expression of NOX4 and NF-κB (Fig.6-4) and increased 
production of free radicals caused by MG and high glucose (Figs. 6-5, 6-6). Oxidative stress can 
be increased by multiple mechanisms. MG is a key inducer of oxidative stress (Desai et al., 
2008) and scavenging MG would prevent activation of multiple pathways of increased free 
radical generation. 
Arginase has also been implicated in causing endothelial dysfunction, mainly by 
competing with eNOS for the common substrate, L-Arg (Berkowitz et al., 2003; Romero et al., 
2008). If L-Arg and D-Arg are to be used to attenuate the effects of MG or high glucose, then 
their effects on arginase activity have to be considered. High glucose has been reported to cause 
increased expression of arginase in endothelial cells (Romero et al., 2008). The effect of MG on 
arginase has not been studied. We report for the first time that MG increases arginase I and II 
expression in endothelial cells and VSMCs. We also found that high glucose also increases 
arginase I and II expression in VSMCs (Fig. 6-3) besides endothelial cells. L-Arg and D-Arg 
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attenuated the increased arginase expression caused by MG and high glucose in both cell types 
(Fig. 6-3), possibly by scavenging MG. MG and high glucose also increased the activity of 
arginase, which seems to be independent of increased protein expression because, even when the 
protein expression of arginase was normalized by co-treatment with MG or high glucose and L-
Arg or D-Arg, we still observed increased arginase activity (Fig.6-3). Moreover, L-Arg and D-
Arg alone did not increase arginase activity. While, the increased arginase activity seen with MG 
or high glucose plus L-Arg can be explained by increased substrate availability, the increased 
arginase activity seen with MG or high glucose plus D-Arg is surprising and needs further 
evaluation. One very assuring finding is that the use of L-Arg or D-Arg to prevent the 
deleterious effects of MG and high glucose on endothelial function or possibly on other 
biological functions, will not be compromised by their effects on arginase or eNOS.  
A major deleterious effect of high glucose and reactive diacrbonyl metabolic 
intermediates, such as MG, glyoxal and 3-deoxyglucosone, is the formation of AGEs (Ahmed et 
al., 1997; Glomb et al., 2001; Kilhovd et al., 2003; Shipanova et al., 1997), which are strongly 
implicated in the pathogenesis of several conditions such as vascular complications of diabetes, 
neurodegenerative diseases, atherosclerosis and aging (Vlassara et al., 1994). The attenuation of 
the formation of the MG-specific AGE, CEL, in VSMCs (Fig. 6-7) is very promising in this 
regard. Prevention of dicabonyls-induced AGEs, which is a major source of AGEs formation 
(Kilhovd et al., 2003; Mostafa et al., 2007; Vlassara et al., 1994), by safer and specific 
scavengers of reactive dicarbonyls is an attractive therapeutic option. The potential of L-Arg and 
D-Arg in this regard is discussed below.  
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Besides its effects on endothelial function, MG has other effects. Thus, acute and chronic 
MG cause pancreatic β cell dysfunction, reduced adipose tissue glucose uptake, reduced insulin 
secretion and type 2 diabetes in Sprague-Dawley rats (Dhar et al., 2010a; Dhar et al., 2011). MG 
has been shown to modify insulin making it dysfunctional (Jia et al., 2006), and LDL making it 
more atherogenic (Rabbani et al., 2011). Scavengers of MG can be very effective in preventive 
strategies against the deleterious effects of hyperglycemia, hyperfructosemia (another source of 
MG) (Dhar et al., 2008) and elevated MG levels.  
Unfortunately, specific and safe MG scavengers are not available. The compounds 
currently used for their MG scavenging ability are non-specific and have other effects, which 
can even be toxic. Aminoguanidine is the most widely used MG scavenger and AGEs inhibitor 
(Brownlee et al., 1986; Edelstein et al., 1992), which unfortunately proved toxic in clinical trials 
(Bolton et al., 2004; Freedman et al., 1999). Metformin, an orally used drug to reduce 
hyperglycemia in type 2 diabetes, and N-acetyl cysteine also have MG scavenging ability but 
have other effects (Beisswenger et al., 2003; Jia et al., 2007; Millea, 2009; Ruggiero-Lopez et 
al., 1999; Vasdev et al., 1998). MG has great affinity for L-Arg and is proposed to react rapidly 
with the guanidino group of L-Arg (Takahashi, 1977). Since arginine has strong affinity for MG, 
it is highly likely that arginine binds MG, administered from outside and produced from glucose 
and other sources in the body, and thus, attenuates the deleterious effects of MG and high 
glucose on endothelial function. While L-arginine is used as a nutritional supplement, it is a 
substrate for five different enzymes including eNOS and arginase (Morris, 2009). The metabolic 
consequences of orally administered L-Arg, which is known to enter multiple metabolic 
processes in the liver and the body, are difficult to predict. D-Arg, the inactive isomer of L-Arg, 
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may prove to have more attractive pharmacokinetic and pharmacodynamic properties, and 
therapeutic potential than L-Arg, if its MG scavenging ability can be demonstrated to be specific 
at multiple functional and biochemical levels. Thus, D-Arg needs to be evaluated more 
rigorously for its pharmacokinetic properties and metabolic fate.    
In conclusion, L-Arg and D-Arg attenuate MG and high glucose induced endothelial 
dysfunction, by an eNOS independent mechanism, most probably by binding and inactivating 
MG, given from outside or produced from high glucose. MG increases arginase I and II 
expression and activity. L-Arg and D-Arg attenuate the increased protein expression but not the 
increased activity of arginase induced by MG and high glucose, which did not restrict the 
attenuation of endothelial dysfunction. The effects of L-Arg and D-Arg on the other deleterious 
effects of MG and high glucose, need to be evaluated by many more separate studies, for 
example on MG-induced pancreatic islet dysfunction and insulin resistance, before definitive 
statements on their therapeutic potential can be made.   
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Figure 6-1. L-arginine and D-arginine attenuate MG and high glucose induced, but not 
inhibition of eNOS-induced, reduced endothelium-dependent relaxation in isolated aortic 
rings from Sprague-Dawley rats. 
120 
 
Concentration-related responses were obtained to ACh in phenylephrine (PE, 1 μM) 
precontracted rings before (control) and 2 h after incubation with MG (100 μM) (A and B), or 
glucose (Glu, 25 mM) (C and D) or 15 min after incubation with the eNOS inhibitor L-NAME 
(10 µM) (E and F). In some sets of rings L-arginine (L-Arg, 300 µM) or D-arginine (D-Arg, 300 
µM) was preincubated for 15 min followed by co-incubation for 2 h with MG (100 μM) (A and 
B), or Glu (25 mM) (C and D) or for 15 min with L-NAME (10 µM) (E and F). (n = 6 rings from 
different rats for each treatment group). *P<0.05, **P<0.01, ***P<0.01 vs. corresponding 
control values. 
†
P<0.05, 
††
P<0.01, 
†††
P<0.001 vs. corresponding L-Arg or D-Arg co-treated 
values. 
‡‡
P<0.01, 
‡‡‡
P<0.001 vs. corresponding control values. 
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Figure 6-2. Exogenous methylglyoxal (MG) and high glucose and increase cellular MG 
levels in cultured vascular smooth muscle cells: attenuation by L-arginine and D-arginine.  
Confluent rat aortic vascular smooth muscle cells were incubated with normal culture 
medium (Control, Con) or medium containing  MG (30 μM) (A), or glucose (25 mM) (B), for 24 
h. L-arginine (L-Arg, 300 μM) or D-arginine (D-Arg, 300 μM) was incubated alone or with  MG 
(30 μM) (A) or glucose (25 mM) (B) for 24 h. Cellular MG was measured by HPLC. n = 6 for 
each treatment. ***P<0.001 vs. corresponding control value, 
†††
P<0.001 vs. corresponding MG 
(30 μM) (A), or glucose (25 mM) value (B). 
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Figure 6-3. Attenuation by L-arginine and D-arginine of methylglyoxal (MG) and high 
glucose-induced increased protein expression, but not activity of arginase (Agn) I and II in 
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cultured human umbilical vein endothelial cells (HUVECs) and vascular smooth muscle 
cells (VSMCs).  
Cultured confluent HUVECs (A, C) or VSMCs (A-10 cell line) (B, D, E) were incubated 
with MG (30 µM) or glucose (Glu, 25 mM) for 24 h. In separate dishes L-arginine (L-Arg, 300 
µM) or D-arginine (D-Arg, 300 µM) was incubated alone (E) or coincubated with MG (30 µM) 
or glucose (25 mM) for 24 h following which the arginase I and arginase II proteins were 
determined by western blotting (A-D). In (E) an arginase activity assay was performed 24 h after 
the treatments, based on conversion of arginine to orinithine and urea, using an activity assay kit. 
n = 6 for each group.  ***P<0.001 vs. control, 
††
P<0.01, 
†††
P<0.001 vs. corresponding MG 30 
μM or glucose 25 mM value. 
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Figure 6-4. Attenuation by L-arginine and D-arginine of methylglyoxal (MG) and high 
glucose-induced increased protein expression of nuclear factor kappa B (NF-κB) and 
NADPH oxidase 4 (NOX-4) in cultured human umbilical vein endothelial cells (HUVECs) 
and vascular smooth muscle cells (VSMCs).  
Cultured confluent HUVECs (A, C) or VSMCs (A-10 cell line) (B, D) were incubated 
with MG (30 µM) or glucose (Glu, 25 mM) for 24 h. In separate dishes L-arginine (L-Arg, 300 
µM) or D-arginine (D-Arg, 300 µM) was coincubated with MG (30 µM) or glucose (25 mM) for 
24 h following which the NF-κB and NOX-4 proteins were determined by western blotting. 
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Figure 6-5. Attenuation by L-arginine and D-arginine of methylglyoxal (MG) and high 
glucose-induced increased reactive oxygen species production in cultured human umbilical 
vein endothelial cells (HUVECs).  
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Incubation of cultured HUVECs with MG (30 µM) (A), or MG (100 µM) (B) or glucose 
(25 mM) (C) for 3 h or 24 h increased  reactive oxygen species (ROS) production, measured as 
oxidized dichlorofluorescein (DCF), which was attenuated by co-incubation with either L-
arginine (L-Arg, 300 µM) or D-arginine (D-Arg, 300 µM). n = 8 for each group. **P<0.01, 
***P<0.001 vs. corresponding control, 
†††
P<0.001 vs. corresponding MG (30 µM), or MG (100 
µM), or glucose (25 mM) value. 
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Figure 6-6.  Attenuation by L-arginine and D-arginine of methylglyoxal (MG) and high 
glucose-induced increased reactive oxygen species production in cultured rat aortic 
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vascular smooth muscle cells (VSMCs).  
Incubation of cultured VSMCs (A-10 cell line) with MG (30 µM) (A), or MG (100 µM) 
(B) or glucose (25 mM) (C) for 3 h or 24 h increased  reactive oxygen species (ROS) production, 
measured as oxidized dichlorofluorescein (DCF), which was attenuated by co-incubation with 
either L-arginine (L-Arg, 300 µM) or D-arginine (D-Arg, 300 µM). n = 8 for each group. 
***P<0.001 vs. corresponding control, 
†††
P<0.001 vs. corresponding MG (30 µM), or MG (100 
µM), or glucose (25 mM) value. 
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Figure 6-7. Detection of methylglyoxal-induced advanced glycation endproduct (AGESs). 
N
ε
-carboxyethyl-lysine (CEL).  
AGEs in cultured rat aortic vascular smooth muscle cells (A-10 cells) were detected after 
incubation with MG (30 µM) or glucose (25 mM) alone, or coincubated with either L-arginine 
(L-Arg, 300 µM) or D-arginine (D-Arg, 300 µM) for 24 h. Immunocytochemistry was performed 
on fixed cells with specific CEL antibody and fluorescein isothiocynate (FITC) conjugated 
secondary antibody. Scale bar 10 µm.  
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Incubation 
Time 
MG (30 
μM) 
Alone 
MG (30 
μM) +L-
Arg (300 
μM) 
MG (30 
μM) +D-
Arg (300 
μM) 
MG (30 
μM) + NAC 
(600 μM) 
NAC 
(600 
μM) 
L-Arg 
(300 
μM) 
D-Arg 
(300 
μM) 
15 min 26.7 ± 0.7 12.6 ± 0.7*** 12.2 ± 0.6*** 15.2 ± 0.7*** 0 0 0 
30 min 26.2 ± 0.7 7.4 ± 0.5*** 7.00 ± 0.3*** 8.8 ± 0.6*** 0 0 0 
60 min 27.2 ± 0.6 5.7 ± 0.2*** 4.3 ± 0.12*** 7.00 ± 0.3*** 0 0 0 
3 h 27.6 ± 0.6 3.5 ± 0.09*** 2.1 ± 0.05*** 5.3 ± 0.06*** 0 0 0 
24 h 26.3 ± 0.6 1.2 ± 0.07*** 0.8 ± 0.08*** 2.7 ± 0.08*** 0 0 0 
 
Table 6-1. Methylglyoxal incubation assay 
Methylglyoxal (MG) was incubated with L-arginine (L-Arg), D-arginine (D-Arg) or N-
acetyl cysteine (NAC) in PBS at 37º C for different times. The solution was analyzed for free 
MG by HPLC after the given incubation period. The values are expressed as mean ± SEM (n = 6 
each). *** P < 0.001 vs. MG alone. 
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CHAPTER 7 
 
DISCUSSION AND CONCLUSIONS 
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7.1 GENERAL DISCUSSION 
The association of diabetes and hypertension is well known. It adds to the treatment 
challenges of diabetes. The pathogenesis of hypertension in diabetics is unclear. For example, it 
is not clear if it is due to hyperglycemia per se or due to insulin resistance or some other cause. It 
may even be due to obesity (Go et al., 2013; Landsberg et al., 2013) which is the highest risk 
factor for type 2 diabetes. Up regulation of the RAAS has been reported in diabetes (Hsueh and 
Wyne, 2011; Goossens, 2012). Our lab has reported an elevated level of plasma and tissue MG 
in SHR and fructose fed SD rats, an animal model of insulin resistance that also develops 
hypertension (Wang et al., 2005; Wang et al., 2008). High fructose-diet in SD rats (Wang et al., 
2008) had increased plasma and aortic MG levels, and significantly increased BP. However, the 
molecular mechanisms were not examined and it was not clear whether the elevated MG levels 
were the cause or effect of hypertension. For example, one popular theory proposes that 
metabolism of fructose by fructokinase, mainly in the liver, consumes ATP and raises tissue and 
plasma levels of uric acid (Johnson et al., 2007; Stirpe et al., 1970). Elevated uric acid reduces 
NO production in endothelial cells and the kidney, and causes endothelial dysfunction and 
increased renin secretion (Mazzali et al., 2001). Thus, in the high fructose-diet study (Wang et 
al., 2008) it is possible that elevated BP may be caused by increased MG levels. Similarly, in the 
SHR (Wang et al.., 2004; Wang et al., 2005), it was not clear whether the hypertension was 
caused by elevated MG in the plasma, the aorta and the kidney. The molecular mechanisms were 
not addressed in these studies.  To evaluate whether MG is directly involved in the pathogenesis 
of hypertension, the logical step was to administer MG to normal animals, such as Sprague-
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Dawley rats and to investigate whether it induces hypertension and if so what is/are the possible 
mechanism/s. 
MG was administered to SD rats for some preliminary data. It is a known fact that MG is 
a potent inducer of oxidative stress, and oxidative stress has been implicated as one of the 
causative factors of hypertension. Also, up regulation of the RAAS has been reported in 
hyperglycemia. Increased oxidative stress and RAAS are known to feed each other (Hitomi et 
al., 2007). Since increased MG, oxidative stress, and RAAS have links it was hypothesized that 
MG up regulates RAAS, but this idea has not been tested before. Some common mediators of the 
RAAS are the AT1 receptor for angiotensin, Ang II and adrenergic α1 receptor. It was therefore 
decided to look at these parameters in cultured VSMCs treated with MG or high glucose. The 
initial experiments on VSMCs treated with MG were positive. Therefore, I made a protocol to 
treat SD rats with MG. 
 MG was administered to rats in drinking water in preliminary studies, and it did not 
significantly increase the plasma MG levels. One possible reason for this could be that MG being 
highly reactive is likely to react with proteins in the epithelial cells of the intestines, as reported 
in one study (Baskaran et al., 1990). This might hinder the absorption of MG. MG is most likely 
generated continuously within the body from the ongoing metabolic processes. To simulate this 
situation as best as possible, MG was administered by continuous infusion with a minipump. Our 
lab has had great success with this mode of administration in a previous study (Dhar et al., 2011) 
where the plasma concentration significantly increased to values reported in pathological 
conditions.  
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Treatment of SD rats with MG for 4 weeks resulted in a significant increase in the BP, 
and MG in the plasma, aorta and the kidney. The kidney plays a major role in BP regulation and 
RAAS activity, therefore, elevation of renal MG levels was of great interest. There was an 
elevation of plasma catecholamines, renin, angiotensin and aldosterone levels in MG treated rats, 
which was building up our evidence of up regulated RAAS. The effectors of RAAS were 
investigated and there was an increased expression of angiotensinogen, AT1 , α1D, and renin in 
aorta and/or kidney of MG treated rats. One reason for choosing the aorta is that the expression 
of tissue RAAS has been well studied in the aorta (Campbell, 1987; Holycross et al., 1992; 
Naftilan et al., 1989). For example, the activity of VSMCs RAS is increased in conditions such 
as hypertension and atherosclerosis (Dzau, 1993). There were not enough of fat free mesenteric 
vessels to determine angiotensinogen, AT1, α1D in this tissue. To investigate the possible 
molecular mechanisms of how MG caused up regulation of the RAAS, cultured VSMCs were 
used, where interference from interacting factors found in vivo can be avoided. Normally, 
activation of a receptor by a ligand produces its effects through a simple or complicated signal 
transduction process. RAGE is a receptor for AGEs. It has two main functions. The membrane 
bound RAGE is believed to increase oxidative stress in response to stimulation by AGEs. 
However, MG has never been investigated as a ligand for RAGE. This idea was tested for the 
first time, and showed that silencing of RAGE prevented the increase in the expression of NF-
κB, a key trigger of increased oxidative stress (Wu et al., 2002; Desai and Wu, 2008).  So it 
established a likely initiating point for the signal transduction of MG that up regulates the RAAS 
and increases BP. Next I tried inhibiting NF-κB with CAY10512. Surely enough, inhibition of 
NF-κB prevented the increase in AT1 and α1D receptors in VSMCs. Ang II is known to up 
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regulate its own receptor and also NF-κB. To further establish the signal transduction I silenced 
angiotensionogen and was able to attenuate the increase in AT1, α1D, and also NF-κB, caused by 
MG. NF-κB can activate several oxidative stress pathways. 
High dietary carbohydrates have been shown to increase BP in animal and human studies. 
High fructose levels in the diet in the form of sugar and high fructose corn syrup have created 
great controversy about their adverse health effects (Lustig et al., 2012; Lustig, 2010). The main 
dietary carbohydrate in our diet is sucrose, in the form of table sugar and high fructose corn 
syrup (HFCS). Sucrose in the form of table sugar is broken down into one molecule of fructose 
and glucose each in the body. On the other hand high fructose corn syrup is prepared by mixing 
free glucose and fructose in different proprotions. The two most commonly used form of high 
fructose corn syrup are HFCS 55 (55% fructose and 42% glucose) and HFCS 42 (42% fructose 
and 53% glucose) (Fulgoni, 2008). Glucose and fructose are metabolized differently in the body 
(Bruckdorfer et al., 1973; Johnson et al., 2007; Johnson et al., 2009; Nakagawa et al., 2006; 
Wolfe et al., 1977), yet a high glucose, high fructose as well as a high sucrose diet have all been 
shown to increase BP in animal and human studies (Raben et al., 2002; Israel et al., 1983; Tom 
et al., 2011; Kaufman et al., 1991; Hwang et al., 1987; Jia & Wu, 2007). Male SD rats fed a high 
glucose diet developed a 7% increase in BP compared to rats fed a normal diet (Kaufman et al., 
1991). SD rats fed with a diet containing 66% fructose as a percentage of total calories for 
approximately 2 weeks developed a significant increase in systolic BP from 124 ± 2 to 145 ± 2 
(SEM) mmHg, whereas no change occurred in the control group (Hwang et al., 1987). Even 
lower doses of fructose (10% in drinking water) given to SD rats for 8 weeks induced a 
significant increase in systolic BP and microvascular changes in the kidney (Sanchez-Lozada et 
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al., 2007). In a study performed in Dr Wu’s lab, male SD rats fed a 60% fructose diet for 16 
weeks showed an increase in the BP from about 110 mmHg to about 155 mmHg at the end of 16 
weeks of treatment, alongwith an associated increase in serum MG levels from 2.48 ± 0.3 
µmol/L in the control to 4.28 ± 0.5 µmol/L in the fructose treated rats (Wang et al., 2008). The 
increase in the BP in fructose treated rats was attenuated by co-treatment with metformin, a MG 
scavenger (Wang et al., 2008). Although MG was not established as a direct causative factor for 
the increased BP in the study by Wang et al (2008), the finding assumes great significance 
because fructose is a known precursor of MG (Dhar et al., 2008) and serum MG was 
significantly elevated in fructose treated rats (Wang et al., 2008). Fructose is equipotent to 
glucose in producing MG when metabolized (Dhar et al., 2008). In the present study, a high 
fructose-diet was  fed  to SD rats for 16 weeks, and it resulted in a significant increase in the BP, 
MG levels, angiotensin, AT1 receptor, α1D receptor protein and mRNA expression in the aorta 
and the kidney. There was also a significant increase in NF-κB and RAGE protein expression, 
and reduction in GSH levels in both the kidney and the aorta of fructose treated rats. Our results 
strongly support MG as a mediator of the effects of high fructose diet on the RAAS and the BP. 
In one of the ongoing studies in our lab, both high glucose (60% of total calories) and high 
fructose (60% of total calories) diets fed to 10 week old male SD rats for 12 weeks caused a 
similar significant increase in the BP. Thus, the BP in high glucose treated rats was 139 ± 3** 
mm Hg, and in high fructose treated rats it was 136 ± 3* mm Hg, compared to 102 ± 11 mm Hg 
in the control group (*P<0.5, **P<0.01 vs control group) (unpublished results). One limitation in 
comparing the effects of a high fructose diet versus exogenously administered MG on BP and 
other hypertension-associated parameters is that the amount of MG generated from fructose in 
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different organs and tissues can be expected to depend on the amount of fructose metabolized in 
a given organ/tissue. The amount of MG generated from fructose in a given organ/tissue can also 
be expected to be different or similar to exogenously administered MG depending on which 
organs/tissues receive the administered MG.   
One major limitation in designing protocols for this project was the choice of a good MG 
scavenger. The commonly used MG scavengers include aminoguanidine, N-acetyl cysteine and 
metformin. N-acetyl cysteine has marked antioxidant effects which can complicate interpretation 
of results, especially since MG induces oxidative stress. Aminoguanidine is not suitable for in 
vivo studies because of its other effects besides MG scavenging, such as inhibition of NOS and 
histaminase. Aminoguanidine may prove toxic over 16 weeks of administration. Metformin, a 
clinically used compound for type 2 diabetes, is a known MG scavenger and would not cause 
toxicity in a 16 week in vivo study. However, the insulin sensitizing effect of metformin can 
make interpretation of results difficult. To overcome this dilemma to a certain extent, the MG 
scavenging effect of metformin was tested in cultured VSMCs where the in vivo hepatic and 
other effects of metformin would not interfere with results, and the observed results can be 
attributed to metformin’s MG scavenging action. An in vitro MG scavenging assay was also 
performed by incubating MG with metformin (Dhar et al., 2013). The results allowed to me 
conclude that MG is a likely mediator of the hypertensive effects of high fructose, through an up 
regulation of the RAAS.   
Arginine seems to be an attractive potential MG scavenger because of several reasons. 
Arginine has been shown to have affinity for MG and other aldehydes. Arginine is an amino acid 
and supplements of L-Arg are used over the counter for several conditions. Its use in 
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hypertension is based on the assumption of increased availability of NO. If the MG scavenging 
potential can be realized in vivo then it can be an attractive supplement in diabetes. It can be 
argued that besides NOS, L-Arg is a substrate for several other enzymes, such as arginase. This 
can lead to unexpected effects when L-Arg is taken as a supplement. This fact is acknowledged 
and for this reason D-Arg was compared with L-Arg for its MG scavenging action. D-Arg is 
equally effective as a MG scavenger. Important findings will likely emerge when both L-Arg and 
D-Arg are tested in in vivo models of diabetes. Much more remains to be done to establish 
arginine as a safe MG scavenger. 
It is difficult to guage the relative MG scavenging ability of different MG scavengers 
because of their multiple direct and indirect effects. For example, NAC can scavenge MG and it 
is also an antioxidant and it can also increase GHS levels in the body (Jia et al., 2006; Millea, 
2009; Lauterberg et al., 1983; Vasdev et al., 1998). Thus, NAC can decrease MG levels directly 
by scavenging it, and also indirectly by increasing GSH which will incraese degradation of MG 
by the glyoxalsae enzymes. An in vitro incubation assay can be performed using different MG 
scavengers incubated separately with MG for different time periods and measuring free MG at 
timed intervals.   
 
7.2 CONCLUSIONS 
The present study strongly indicates MG as one of the causative factor in the 
pathogenesis of hypertension, especially in high carbohydrate- and diabetes-induced 
hypertension. Although several studies have reported elevated MG levels in hypertensive and 
diabetic conditions, it is not clear whether MG is the cause or effect of these pathological 
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conditions. Chronic MG administration by mini pump for 28 days up regulates components of 
the RAAS in the plasma, kidney and the aorta, and significantly increases BP, which was 
attenuated by a MG scavenger. Activation of RAGE and NF-κB likely mediates the signal 
transduction triggered by MG. High fructose diet treated Sprague-Dawley rats show findings 
similar to MG treated rats and suggest a strong possibility of MG as the mediator of the 
deleterious effects of high fructose on the RAAS and BP. 
The study has shown efficacy of arginine as a MG scavenger in vitro. Incubation of 
VSMCs and HUVECs with glucose and MG increases MG formation, oxidative stress and 
arginase I and II expression and activity, the latter being a novel finding. These effects were 
attenuated by amino acid L- and D-arginine. 
The present study indicates that a high carbohydrate diet may cause daily abnormal 
elevations of MG levels in the plasma and tissues, which could result in vascular pathology. The 
severity and progression of these changes leading to hypertension depends on the health of the 
individual, any underlying oxidative stress, GSH levels and antioxidant defenses. 
In conclusion, MG is one of the causative factors in the pathogenesis of hypertension and 
endothelial dysfunction.  Development of specific MG scavengers like arginine will help prevent 
the progression of high carbohydrate induced hypertension and endothelial dysfunction. 
 
7.3 LIMITATIONS OF THE STUDY 
Peripheral resistance influences the BP. The resistance in small vessels such as the 
second and third order branches of the mesenteric artery contributes to BP regulation. 
Determination of vascular contractility and endothelium-dependent relaxation of small peripheral 
140 
 
resistance vessels is a useful parameter to study in hypertension related studies. I studied 
vascular contractility in aortic rings. The results showed a marginal increase in contractility to 
the α1 selective agonist phenylephrine. I attempted to study contractility with the angiotensin 
AT1 receptor agonist Ang II, but the vessel became desensitized to Ang II after the first dose and 
I was unable to obtain a dose-response curve to Ang II. Vascular smooth muscle contractility 
studies in small resistance vessels using a myograph would have been a useful addition to the 
results and will be a priority consideration in future studies. 
There is a lack of availability of specific and safe MG scavengers. This has been 
discussed in the introduction. Aminoguanidine has other effects besides its MG scavenging 
action and is not an ideal MG scavenger for in vivo experiments. I used alagebrium, which was 
kindly provided by Alteon Inc., USA, in initial experiments. Alagebrium was developed as an 
AGEs breaker but we have shown its MG scavenging action (Dhar et al., 2010a). It is not toxic 
in vivo. However, the company ceased operations and we were not able to replenish our supply 
and had to use aminoguanidine in later studies. Aminoguanidine being toxic in vivo we used 
metformin in high fructose treated rats. Metformin is used clinically in type 2 diabetes but is not 
a specific MG scavenger. For this reason the conclusions have been moderated in studies with 
high fructose diet fed rats and metformin. Even though I was convinced that elevated MG 
generation following high fructose intake mediates increased expression of RAAS components, I 
concluded that “we report a strong association between elevated levels of methylglyoxal, RAGE, 
NF-κB, mediators of the renin angiotensin system and blood pressure in high fructose diet fed 
rats.” 
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Another argument can be made that increased BP caused by increased RAAS activity 
should be prevented by inhibitors of angiotensin converting enzyme such as ramipril and 
enalapril, or with angiotensin receptor blockers such as losartan. Therefore, a group treated with 
MG plus an ACE inhibitor or angiotensin receptor blocker should have been included. My 
explanation is that there are many factors, such as inflammation, hyperglycemia, and obesity, 
which can increase RAAS activity. Chronic inflammation itself can occur in many conditions. 
Therefore prevention of increased BP with ACE inhibitors or angiotensin receptor blockers does 
not provide conclusive evidence that a given factor, in this case MG, was responsible for 
increased RAAS expression and BP.  
The BP was measured with a carotid artery catheter at the end of the treatment periods in 
4 week MG treated and 16 week fructose treated rats. While it can be argued that anesthesia can 
affect the recorded BP, I believe that the factor of anesthesia would affect all groups equally, 
including the control group. Therefore, the results bear significance. I tried to measure the BP 
weekly during treatment with a tail cuff system (Harvard Apparatus Canada, Saint-Laurent, QC, 
Canada), but I got very variable results in all groups. The BP value was different in successive 
recordings from the same rat on the same day. I experienced that tail cuff BP recording is not a 
very reliable method. It can be argued that telemetry is a reliable method to measure the BP. 
Telemetry is a very invasive procedure with major drawbacks of expertise needed, the extra post-
surgical recovery time, the increase in expense and the limitations of fewer implants available at 
any given time. It was decided to use the option of telemetry recording if the results were 
inconclusive with carotid artery recording, in a separate follow up project, which was not 
required. 
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It can be argued that 60% calories provided by fructose in the diet is higher than the 10-
15% fructose seen in North American diets, but 60% is widely used in animal studies by 
researchers, and 60% is expected to produce results comparable to 10-15% diet in a shorter time. 
 
7.4 SIGNIFICANCE OF THE STUDY 
Hypertension is a major problem in Canada and the whole world. Adding to the burden is 
the recent alarming epidemic of obesity and type 2 diabetes, attributed in a large part to high 
dietary carbohydrates. The cases of diabetes associated hypertension are bound to increase. For 
practical reasons compounds targeting glucose or fructose molecule itself cannot be used. 
Establishing excessive reactive aldehydes produced from high carbohydrate diet metabolism in 
the pathogenesis of diabetes and hypertension will allow us to develop preventive strategies. 
Preventive strategies will play an important role because the dietary habits of billions of people 
worldwide are unlikely to change overnight or even over the next few years. The results with 
MG have given important clues for more work in high carbohydrate diet induced hypertension. 
Our lab will investigate the potential of arginine as a preventive supplement against MG-induced 
pathology.  
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